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ABSTRACT 
Single-cell proteomics and transcriptomics analysis are crucial to gain insights of 
healthy physiology and disease pathogenesis. The comprehensive profiling of 
biomolecules in individual cells of a heterogeneous system can provide deep insights into 
many important biological questions, such as the distinct cellular compositions or 
regulation of inter- and intracellular signaling pathways of healthy and diseased tissues. 
With multidimensional molecular imaging of many different biomarkers in patient 
biopsies, diseases can be accurately diagnosed to guide the selection of the ideal treatment. 
As an urgent need to advance single-cell analysis, imaging-based technologies have 
been developed to detect and quantify multiple DNA, RNA and protein molecules in single 
cell in situ. Novel fluorescent probes have been designed and synthesized, which targets 
specifically either their nucleic acid counterpart or protein epitopes. These highly 
multiplexed imaging-based platforms have the potential to detect and quantify 100 
different protein molecules and 1000 different nucleic acids in a single cell. 
Using novel fluorescent probes, a large number of biomolecules have been detected 
and quantified in formalin-fixed paraffin-embedded (FFPE) brain tissue at single-cell 
resolution. By studying protein expression levels, neuronal heterogeneity has been revealed 
in distinct subregions of human hippocampus. 
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CHAPTER 1 
INTRODUCTION 
1.1 Single-cell biology 
Biological systems are often composed of molecularly and functionally distinct cells. Such 
heterogeneity is present not only in multicellular tissues such as nervous or cancer tissues, 
but also in isogenic bacterial and yeast cells1. Cell heterogeneity has also been increasingly 
recognized as a critical feature of many biological processes, such as metastasis2, cancer 
cell response to drugs3-6, immune response7, and cell differentiation8. Various factors can 
lead to cell heterogeneity, including different genetics or epigenetics, distinct 
microenvironments, or stochastic gene expression. The differences between individual 
cells in a biological system may have significant consequences in the function and health 
of the entire system. However, many biological experiments are performed on groups of 
cells, which can obscure the important differences between individual cells. Therefore, 
single-cell analysis is in a critical need to advance our understanding of normal cell 
physiology and disease pathogenesis. 
1.2 Multiplexed single-cell protein detection 
Understanding how cellular regulatory networks function in normal cells and malfunction 
in diseases is an important goal of post-genomic research9. Due to the inherent complexity 
of regulatory networks, comprehensive molecular profiling is required to infer the 
functions of different biomolecules in a pathway and to detect altered gene expression in 
diseases. To enable highly multiplexed single-cell DNA or RNA analysis, many 
technologies have been developed recently1, 10-14. However, such nucleic acids analysis 
generates an incomplete picture to characterize the cells, as it fails to provide information 
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on proteins, which are central to many biological processes, such as transporting molecules, 
catalyzing biochemical reactions, regulating signal transduction, controlling gene 
expression, among others. In addition, studies have shown a weak correlation between 
RNA expression and protein abundance15, 16. For these reasons, there remains a substantial 
need to develop novel single-cell proteomic technologies, which will allow us to study 
protein expression, location, transportation, posttranslational modifications, and 
interactions with other proteins and biomolecules. 
The major challenges for single-cell protein analysis include the low abundance of 
proteins in individual cells and the inability to amplify proteins. Thus, to detect proteins in 
single cells, extremely sensitive assays are required. Conventional proteomic technologies, 
such as mass spectrometry17 and microarray18; do not have such high detection sensitivity, 
and require the proteins from pools of cells to be analyzed together. As a result, these 
technologies mask the single-cell variations in a population. Fluorescence microscopy and 
flow cytometry have been routinely used to quantify proteins in individual cells19. 
Nonetheless, due to the spectral overlap of commonly available organic fluorophores or 
fluorescent proteins, these imaging based approaches can only detect a handful of different 
proteins in one sample20. Therefore, to enable single-cell proteomic analysis, new methods 
with high detection sensitivity and multiplexing capability have to be developed. 
Here I review the recent advances in the development of single-cell proteomic 
technologies. The microchip- or mass cytometry-based approaches enable multiplexed 
protein analysis in isolated cells; while the in situ proteomic methods allow comprehensive 
protein profiling in their native spatial contexts in intact tissues. Different platforms may 
have varied sample throughput, multiplexing capacity, detection sensitivity, and assay cost. 
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Sample throughput is used to characterize the number of cells that can be profiled in one 
experiment, and multiplexing capacity indicates how many proteins can be quantified in 
individual cells. Each approach discussed here has unique advantages. The selection of a 
specific method should be determined by the biomedical questions under study. 
1.2.1 Single-cell barcode chips 
To enable multiplexed protein analysis in individual cells, the Heath group developed the 
single-cell barcode chips (SCBC)7. In this approach, single cells are compartmentalized 
into more than one thousand microchambers. Each microchamber contains an antibody 
barcode array, patterned as parallel stripes. This antibody barcode array can capture the 
secreted proteins from single cells. The captured proteins are then detected by the 
corresponding biotinylated antibodies, and subsequently stained by fluorescent 
streptavidin. The generated fluorescence signals are compared with a calibration curve to 
determine the abundances of the secreted proteins. Alternatively, the captured proteins can 
be directly analyzed by mass spectrometry to quantify their identities and amount. A 
critical requirement for the success of SCBC is to prepare the miniaturized antibody 
barcodes. To achieve this, the DNA-encoded antibody library (DEAL) technology has been 
developed21, 22. In this method, oligonucleotides are first immobilized on polylysine-coated 
surface as highly dense and uniform barcodes using microfluidics flow channels. To 
convert these DNA barcodes into antibody barcodes, the immobilized oligonucleotides are 
hybridized by DNA–antibody conjugates. The DEAL technology allows up to 20 antibody 
stripes to be patterned in each microchamber. Thus, this spatially barcoded microfluidic 
platform has the potential to quantify 20 varied proteins secreted from single cells. 
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To further increase the multiplexing capacity, the Fan group combined the spatial 
and spectral barcodes on one chip23. Each microchamber in this platform contains 15 
separated antibody stripes, and each stripe is composed of three different antibodies. The 
secreted proteins captured on these three antibodies are later stained by blue, green and red 
detection antibodies, respectively. Combining the spatial and spectral barcodes, this 
technology enables the quantification of 45 different proteins secreted from single cells, 
which represents the highest multiplexing capacity for the SCBC assay to date. 
Compared with other single-cell genomic technologies, SCBC has two major 
advantages. First, SCBC enables the quantification of the secreted proteins from live cells, 
whereas other platforms can only detect intracellular or membrane proteins. Second, by 
lysing the cells in the microchambers, SCBC is able to analyze secreted, cytoplasmic and 
membrane proteins together with metabolites from the same single cells24, 25. Despite its 
advantages, SCBC has some limitations. For example, a compromise has to be made 
between its multiplexing capacity and detection sensitivity. To increase the multiplexing 
capacity by patterning more antibody stripes in each microchamber, the chamber volume 
has to be enlarged, which reduces the protein concentrations and consequently sacrifice the 
detection sensitivity. To immobilize several antibodies in each stripe can also improve the 
multiplexing capability. However, in these antibody stripes, the amount of each antibody 
is decreased, leading to reduced sensitivity. Additionally, SCBC can also be limited by the 
complex antibody barcodes fabrication, low throughput to analyze cytoplasmic proteins, 
and sometimes the lack of high-quality capture and detection antibody pairs for the protein 
targets. 
1.2.2 Single-cell western blots 
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Almost all the single-cell proteomic technologies rely on antibodies to detect the protein 
targets. This antibody-dependence can restrict analysis accuracy, as antibody cross-
reactivity and non-specific binding can generate false positive signals. To address these 
issues, the Herr group developed single-cell western blots (scWesterns)26, 27. The 
scWesterns array is comprised of more than six thousand microwells. Each microwell is 
20 mm in diameter, and patterned in a 30 mm thick photoactive polyacrylamide gel on a 
microscopic slide. Individual cells are first settled into microwells, and lysed with a 
denaturing buffer. Subsequently, the proteins with different molecular mass are separated 
by polyacrylamide gel electrophoresis (PAGE). The separated proteins are then 
immobilized onto the benzophenone-containing gel by UV exposure. Finally, the targeted 
proteins are detected by sequential diffusion of primary and fluorescently labeled 
secondary antibodies. Since the proteins are covalently bonded to the gels, a strongly 
denaturing buffer can be applied to strip the antibodies. Through reiterative cycles of 
antibody stripping and target reprobing, multiplexed protein analysis can be achieved. 
scWesterns is less affected by antibody cross-reactivity, as proteins are separated by their 
molecular mass before antibody staining. This allows the on-target and off-target signals 
to be clearly differentiated. Recently, the Herr group incorporated the isoelectric focusing 
(IEF) assay into the scWesterns array, which can even resolve protein isoforms differing 
by a single-charge unit28. However, since 40%, 72% and up to 50% of the proteins can be 
lost during cell lysing, protein immobilization and repeated antibody stripping26, 
scWesterns may have limited detection sensitivity. 
1.2.3 Antibody barcoding with cleavable DNA 
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To further increase the multiplexing capacity of the single-cell proteomic technologies, the 
Weissleder group developed antibody barcoding with cleavable DNA (ABCD)29, 30. In this 
approach, each different antibody is tethered with a unique DNA barcode (70 mer) through 
a photocleavable linker. After antibody incubation, cells are exposed to ultraviolet light to 
release the unique DNA barcodes by cleavage of the linker. Fluorescence hybridization 
technique is utilized to detect the unique barcode sequences, which are translated to protein 
expression levels. This antibody barcoding technology has the highest multiplexing 
capacity among all the current single-cell proteomic assays. However, as the barcodes 
released from each cell have to be analyzed on one hybridization chip, this approach is 
limited by its low throughput. To address this issue, CITE-seq was developed31. By 
encapsulating single cells into water droplets in a microfluidic apparatus and subsequently 
sequencing the cleaved DNA barcodes, CITE-seq enables thousands of single cells to be 
profiled in one experiment. For these antibody barcoding methods, the transcripts and the 
cleaved DNA barcodes from the same cell can be analyzed together. Therefore, these 
approaches allow combined RNA and protein quantitation. Nonetheless, due to the non-
specific binding between DNA barcodes and cellular endogenous molecules or between 
different DNA barcodes, it can be difficult to precisely quantify low-abundance proteins 
applying these methods. 
1.2.4 Mass cytometry 
To enable high-throughput single-cell proteomic analysis, the Nolan group developed mass 
cytometry32. This approach is a fusion of flow cytometry and elemental mass spectrometry, 
and integrates their advantages to allow highly multiplexed protein analysis in a large 
number of single cells. In mass cytometry, antibodies coupled to distinct metal isotopes are 
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used to bind their corresponding protein targets on and within cells. Subsequently, cells are 
sprayed as single-cell droplets, and transported into plasma by laminar flow of argon gas. 
After individual cells are vaporized, atomized and ionized, a time-of-flight (TOF) mass 
spectrometer is used to quantify the generated ions. The signal for each metal isotope is 
integrated and translated to the abundances of the proteins in single cells. With 1000 cells 
analyzed per second, mass cytometry has the highest throughput among all the single-cell 
proteomic technologies. However, this approach also has some limitations. For example, 
the enriched metal isotopes typically contain 1% of isotope impurities, which can generate 
misleading background signals. Additionally, some isotope ions form oxide in the plasma. 
The increased mass ([M+16] can interfere with the accurate data analysis. Moreover, mass 
cytometry analyzes only 30%–40% of the injected cells, which hinders its application to 
study samples with small cell numbers. Finally, as cells are atomized, they cannot be 
recovered for subsequent study or analysis. 
1.2.5 Mass spectrometry imaging 
To enable in situ proteomic analysis in individual cells, two mass spectrometry (MS) 
imaging based methods33, 34 have been developed. In these approaches, metal isotopes 
labeled antibodies are used to detect their corresponding protein targets. Next, either a laser 
or ion beam converts the specimen spot-by-spot into a stream of particles. The content of 
the metal isotopes contained in these particles is determined by a mass spectrometer. Then, 
computer software is applied to reconstruct a two-dimensional image using the mass data 
together with its location information. Compared with fluorescence imaging, these MS 
imaging based approaches avoids the background signals generated by cellular 
biomolecules, as only non-biological metal isotopes are used to label antibodies. 
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Additionally, these methods allow a large number of different proteins to be stained 
simultaneously by antibodies conjugated with varied metal isotopes, which minimizes 
epitope decay and image registration. However, the current MS imaging methods have low 
sample throughput, since it takes them eight hours to analyze a 1 mm2 sample33, 34. 
Moreover, the high-resolution imaging mass spectrometers are expensive and rare in 
academic institutions, which may limit their broad applications. 
1.2.6 Cyclic immunofluorescence 
To enable high-throughput in situ proteomic analysis with a standard instrument, cyclic 
immunofluorescence has been explored35-43. This approach consists of three major steps in 
each immunofluorescence cycle. First, different antibodies labeled with distinct 
fluorophores are used to stain their corresponding protein targets in cells or tissues. In the 
second step, fluorescence images are captured in each fluorescence channel to allow 
protein profiling in their native spatial context. Finally, the fluorescence signals are 
removed to initiate the next immunofluorescence cycle. Through reiterative cycles of target 
binding, fluorescence imaging and fluorescence signal removal, comprehensive protein 
profiling can be achieved. For example, with M sequential immunofluorescence cycles and 
N proteins analyzed in each cycle, an overall M x N protein targets can be profiled in the 
same specimen in situ. Compared with MS imaging, cyclic immunofluorescence has 
significantly higher throughput, as large imaging areas can be acquired in milliseconds to 
seconds. Furthermore, since the only required instrument is a common fluorescence 
microscope, this approach can be easily adopted by different research laboratories.  
 A critical requirement for the success of cyclic immunofluorescence is to remove 
the fluorescence signals efficiently while maintaining the integrity of the protein targets. 
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In this way, the signal removal process and the minimum signal leftover will not interfere 
with the protein analysis in subsequent cycles. To achieve this, the Schubert group has 
developed the photobleaching based approach to erase the fluorescence signals41. This 
approach has been successfully applied for comprehensive protein profiling in cells and 
tissues. However, as different images areas have to be photobleached sequentially, this 
photobleaching based method suffers from long assay time and low throughput. To address 
these issues, chemical bleaching has been explored to remove the signals37, 38. With H2O2 
in a basic or acidic solution, the fluorophores in the whole specimen can be deactivated in 
less than one hour. Nonetheless, this chemical treatment process may damage some 
epitopes, and not all the proteins can be quantitatively profiled in the later cycles. To enable 
fluorescence signal removal in a short time, antibody stripping has also been explored39, 40, 
43. In this approach, a basic or acidic solution containing sodium dodecyl sulfate (SDS) is 
applied to break the antibody-antigen interactions and elute the antibodies. Although some 
success has been achieved using this approach, the repeated harsh chemical treatment may 
lead to specimen degradation and loss of protein antigenicity. 
 To remove fluorescence signals under a mild condition, the Diehl group has 
developed the DNA strand displacement based approach35, 36, 42. In this method, antibodies 
conjugated to oligonucleotides are used to detect their protein targets. Subsequently, the 
oligonucleotides on antibodies will recruit fluorescent oligonucleotides by DNA 
hybridization. After imaging, the fluorescent oligonucleotides are removed by strand 
displacement reactions. Using this approach, it has been shown that at least two reiterative 
immunofluorescence cycles can be carried out in the same specimen. However, due to the 
potential mis-hybridization between different oligonucleotides and the nonspecific binding 
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between oligonucleotides and endogenous biomolecules, this approach suffers from the 
limited multiplexing capacity. 
1.2.7 Biomedical application 
The single-cell proteomic technologies discussed here are powerful tools to explore cell 
heterogeneity of complex biological systems. The comprehensive single-cell protein 
profiling generated by these technologies (Figure 1.4.1A) can be analyzed by clustering 
algorithms44, 45; to partition cells with similar expression profiles into subgroups (Figure 
1.4.1B). Applying this approach, the distinct cell subtypes in many complex biological 
systems have been explored. For instance, SCBC7, 23 and mass cytometry46 have been 
applied to investigate the heterogeneity among immune cells. And cancer cell 
heterogeneity has been studied using scWesterns27; ABCD30 and mass cytometry44, 47. By 
enabling in situ protein analysis, mass spectrometry imaging33, 34 and cyclic 
immunofluorescence37, 39, 40, 41, 48-51 have been utilized to unravel the distinct cell subtypes 
in intact tumor and brain tissues. The results generated from these single-cell proteomic 
assays not only advance our understanding of cell heterogeneity and subtype-specific 
protein expressions, but also facilitate the identification of cellular lineage, cell-cell 
interaction and tissue organization. 
 Another exciting application of single-cell proteomic technologies is to interrogate 
intracellular signaling networks. To investigate protein interactions in conventional bulk 
cell experiments, expression variations have to be generated by external stimuli, such as 
small molecule inhibitors, small interfering RNAs or knockout models, etc. These 
experiments generally assume that the upstream and downstream proteins are in a linear 
relationship. However, most signaling cascades function with thresholds, such that 
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different spatial and temporal inputs can be integrated to trigger precise signaling 
responses52. Single-cell proteomics can discern these complex details. By taking advantage 
of the expression fluctuation generated naturally in individual cells53-59, single-cell protein 
expression correlation analysis (Figure 1.4.1C) will enable us to study the activating and 
inhibitory interactions between proteins (Figure 1.4.1D). Using this approach, the signaling 
pathways in cancer cells and immune cells have been explored by SCBC24, 
60,scWesterns27,mass cytometry32, 61-64 and cyclic immunofluorescence65. The results 
generated from these studies can refine the existing regulatory pathways, suggest new 
signaling networks, predict the functions of unannotated genes, reveal the pharmacological 
effects of drug molecules, and identify the mechanisms for therapeutic resistance. 
1.2.8 Summary and outlook 
The single-cell proteomic technologies are emerging as powerful toolkits to address 
various important biological and biomedical questions, which can not be answered using 
traditional bulk cell assays. Each of the technologies discussed here has its unique 
advantages. For example, SCBC allows the quantification of secreted proteins from live 
cells. scWesterns avoids the false positive signals generated by antibody cross-reactivity 
and nonspecific binding. Among all the current platforms, ABCD and mass cytometry have 
the highest multiplexing capacity and sample throughput, respectively. And Mass 
spectrometry imaging along with cyclic immunofluorescence enable the protein 
quantification in their native spatial contexts. In addition, many of these complimentary 
technologies can be combined to integrate their advantages. For instance, SCBC and 
ABCD can be applied sequentially to analyze a large number of secreted and cytoplasmic 
proteins from the same cells. After cycles of immunofluorescence with cleavage 
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fluorescent antibodies, the accumulated fluorescence background can be reduced by 
photobleaching or chemical bleaching. And tissues stained by cyclic immunofluorescence 
can be subsequently analyzed by mass spectrometry imaging to increase the multiplexing 
capacity. 
 Although remarkable advances have been made recently to develop single-cell 
proteomic technologies, the low multiplexing capacity still remains their major 
technological bottleneck. The current methods can only quantify dozens of proteins, which 
represents a tiny fraction of the whole proteome. With an increased number of proteins 
quantified in a biological sample, the signaling network and cell heterogeneity can be more 
precisely characterized. The combination of single-cell proteomics with other “omics” 
technologies will partially address this issue. To achieve that, the biological sample can be 
first analyzed by genomics66,transcriptomics67, 68,proteomics69, 70,and metabolomics71, 72 
methods. The identified cell types and active pathways can guide the selection of the 
protein panel. In this way, the most informative proteins can be identified and analyzed in 
the following single-cell proteomic assays. Alternatively, the biological sample can be 
profiled first using single-cell proteomics, to select the cell types or tissue areas of interest. 
These cells or tissue areas can be isolated by microfluidics or microdissection73 methods, 
and then studied using the “omics” technologies. 
 Low detection sensitivities of the current single-cell proteomic technologies limit 
its application to quantify proteins with low expression levels. Almost all the platforms 
discussed here use labeled primary or secondary antibodies to stain target proteins. 
However, to quantify proteins in formalin-fixed paraffin-embedded (FFPE) tissues, the 
most common type of preserved clinical samples74, immunohistochemistry with enzymatic 
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signal amplification is often required75. This signal amplification approach can enhance the 
detection sensitivity by up to 500-fold, as compared with the methods using fluorescent 
antibodies76. Therefore, to quantitatively analyze the low-expression proteins in cells or 
partially degraded proteins in FFPE tissues, the sensitivity of the current single-cell 
proteomic approaches need to be significantly improved. One potential solution to that 
could be to incorporate the enzymatic signal amplification methods into cyclic 
immunofluorescence. In this way, a large number of different proteins can be sensitively 
detected in sequential analysis cycles. 
 Another challenge for single-cell proteomics involves data analysis and 
standardization. To profile individual cells in intact tissues, it is required to segment single 
cells in the tissue image. The stained nucleus and membrane proteins are usually used as 
features for cell segmentation77. Nonetheless, in a typical 2–5 mm thick tissue section, the 
nucleus from certain cells can be missing, and membrane proteins could be at varied 
cellular locations in different cell types or in diseased tissues. These factors can lead to 
mis-identified cellular boundaries and erroneous cell segmentation. To mitigate these 
errors, new algorithms could be developed by using all the stained proteins for cell 
segmentation. Second, most of the existing data analysis methods only apply protein 
abundances to define cell heterogeneity44, 45. The recently developed in situ proteomics 
technologies allow the spatial information to be added for cell characterization. This spatial 
information includes the protein location in the cell, the cell location in the tissue, and the 
molecular states of the adjacent cells, among others. New algorithms using both protein 
abundances and location information to characterize single cells will provide new insights 
into cell-cell communications and the impact of microenvironment on cell fate and 
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function. Third, the current assays apply the relative signal intensities of different bound 
antibodies to infer the abundances of proteins. However, to facilitate accurate comparison 
of the results across varied platforms and over time, it is required to standardize the 
measurements and precisely quantify the amount of the target proteins. To achieve that, 
the samples of interest can be processed in parallel with the standard cells, whose absolute 
protein copy numbers have	been determined by mass spectrometry78 or fluorescent protein 
labels15. By calibrating the results from the sample with the ones from the standard cells, 
one can quantify the absolute protein copy numbers in the given sample. 
 With the ongoing development, single-cell proteomic technologies will 
significantly accelerate our understanding of heterogeneous biological systems. For 
example, solid tumors can be profiled at the single-cell level to explore the molecular 
mechanisms of cancer initiation, progression and metastasis, identify new biomarkers, and 
discover novel drug targets. Another exciting application of single-cell proteomic 
technologies is to study the developing embryo at various developmental stages, to 
investigate how developmental programs and organ formation are executed at the 
molecular level. Additionally, by examining the brain tissues at various anatomical regions 
during different brain activities, we will advance our understanding on how molecular and 
cellular processes collectively cooperate to achieve high-order mental functions, such as 
learning and memory. 
 Single-cell proteomic technologies will also have wide applications in clinical 
diagnosis and precision medicine. By mapping regulatory networks within individual cells 
and interrogating interactions among cells in a tissue, we will enhance our understanding 
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of the molecular mechanisms of diseases, and may discover novel drug targets for more 
effective cellular targeted therapy. New biomarkers can also be identified by pinpointing 
alterations in the abundances and positions of various biomolecules in single cells. With 
comprehensive molecular profiling of a panel of biomarkers in individual cells, diseases 
can be accurately diagnosed and the ideal treatment can be selected. Additionally, the 
efficacy of drugs or immune response can be monitored during the therapy to adjust the 
further treatment timely. We expect that single-cell proteomic analysis will broadly 
complement other “omics” technologies and will become a cornerstone in biomedical 
research and in precision medicine. 
1.3 Multiplexed single-cell transcriptome quantification 
For many decades, cells have been classified based on their morphology and expression of 
marker proteins in functionally distinct settings79-81. Combinatorial separate gene 
expression programs reflect changes in cellular activity and identity82, 83. Proteomic 
technologies have been widely used in clinics for cellular distinctions, and it has an 
advantage of assaying the final product of the gene expression. However, multiplexing of 
single-cell level proteomics is limited due to the availability of antibodies. Additionally, 
proteomics assays are constrained to a limited, pre-selected repertoire of molecules, 
precluding an unbiased, comprehensive analysis of cell phenotypes. In a parallel approach, 
single-cell transcriptomics (the abundance of all transcribed RNAs in a cell) provides an 
alternative to classify and characterize cells at the molecular level84, 85. Microarray 
technologies have been used for transcriptome- or genome-wide nucleic acid analysis86. 
These technologies enabled insights of disease progression, the discovery of new genes 
and drug discovery. However, detection artifacts due to fluorescence-based readouts, mis-
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hybridizations, high detection threshold, and completely lack of quantification limits its 
application to investigate the transcriptome comprehensively87-89. Therefore, to enable 
single-cell transcriptomics analysis, new methods with high multiplexing capacity and 
detection sensitivity have to be developed. 
 Here I review the recent advances in the development of single-cell transcriptomics 
technologies. Single-cell RNA sequencing-based approaches enable multiplexed RNA 
quantification in isolated cells in vitro, while single molecule RNA fluorescent in situ 
hybridization (FISH) -based methods and in situ RNA sequencing-based methods allow 
comprehensive transcript quantification in their native spatial contexts in intact tissues. 
Different platforms may have varied detection sensitivity, multiplexing capacity, sample 
throughput, and assay cost. 
1.3.1 Single-cell RNA sequencing 
Among the single-cell transcriptomics profiling approaches, the most widely used method 
is single-cell RNA sequencing (scRNA-seq), which aims to profile gene expression in cells 
comprehensively and to uncover previously unrecognized factors due to a basis toward pre-
characterized genes. All single-cell RNA seq methods have a similar initial step, in briefly, 
RNAs are captured from the cell based on the characteristic of poly(A) tail of mRNA. The 
RNA is then fragmented of about 200 nucleotides and converted to cDNA by random 
primers. The next step is an amplification of cDNA using either polymerase chain reaction 
(PCR) of in vitro transcription (IVT). The cDNA libraries are sequenced and mapped back 
with the reference genome. The reads are counted and normalized to obtain transcript copy 
number in single-cell. Single-cell RNA sequencing can lead to identifying new genes, and 
gene isoform variability as this method is based on direct sequencing. 
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Eberwine et al used in vivo reverse transcription (RT) to measure the expression of 
a handful of individual genes from single cells for the first time in 199290. Later, PCR-
based methods and the number of genes and cells can be assayed, scaled up91. Eventually, 
Tang et al investigated utterly unbiased transcriptome-wide of the mRNA in a single cell, 
using high throughput DNA sequencing92. 
Early single cell experiments had limited throughput to sequence enough cells to 
get statistically relevant data and mostly were motivated by the prospect of an in-depth 
analysis of gene expression in a few precious cells92, 93-96. A shift in the field came when 
Guo et al performed RT-qPCR of 48 genes in parallel on more than 500 cells and identified 
distinct cell types without pre-sorting, demonstrating the utility of measuring a larger 
number of cells97. To attempt high throughput sequencing, Fluidigm C1 microfluidics chip 
platform is used to capture cells into micro-wells98. In this method, cells are dissociated 
from a tissue and cells suspension passed into the integrated fluidic circuit (IFC) of the C1 
device, which can capture 800 cells. Cells are stained and imaged to check the viability of 
the cells. The IFC is placed in the C1 device to lyse the cells and subsequently converted 
to cDNA and amplifies its content for each cell. The output of the C1 is then sequenced to 
get single-cell data. Fluidigm platform increases the throughput of single-cell sequencing; 
however, it suffers from low amplification efficiency. Additionally, the number of cells 
can be sequenced is not statistically meaningful enough for heterogeneous tissue in a cost-
effective manner. 
To increase the throughput of single-cell RNA sequencing, two competing droplet-
based methods have been introduced, named Drop-seq and in-Drop98-100. These two 
methods are cost-effective and can sequence thousands of cells in a relatively short period. 
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In these methods, they utilized microfluidic droplets, which is containing a bead coated 
with barcoded primers to capture cells and identify them. 
Single-cell RNA sequencing can survey the diversity of cell types within a sample. 
Analyzing a large number of cells, this method has potential to catalog distinct cell types 
in an unbiased and reproducible manner. However, it suffers from low mRNA capture 
efficiency. Additionally, these methods can only be used reliably to quantify high 
expression genes or genes with a high degree of variability between samples. Moreover, 
cost of sequencing, substantial inefficiencies of cell isolation, and lack of spatial resolution 
of single-cell RNA sequencing limit its broader application in biomedical sciences. 
1.3.2 Single-cell sequencing in situ 
An alternative to RNA sequencing is to sequence RNA directly in situ inside the cells. In 
situ sequencing101-103 has been developed, it uses to target padlock probes to generate 
rolling circle amplification products to a predetermined set of target genes. In one 
approach, 32 targets in breast cancer sample were resolved by using four barcode 
nucleotides in the padlock probe and sequenced in situ101. In contrast, FISSQ approach 
sequences the amplified RNA content in situ directly102. For example, by reading 27 bases 
of each transcript, 8000 different transcripts are detected across cultured fibroblasts. 
However, in situ sequencing methods suffer from low detection efficiency and may miss 
transcripts with low copy numbers. 
1.3.3 Single-cell spatial transcriptomics 
Spatial context of cells is an essential factor in a cellular heterogeneity of tissues. In a 
suspension of cells, spatial information is completely lost. Single molecule fluorescent in 
situ hybridization (smFISH) has emerged as a powerful tool to quantify target genes of a 
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single cell in their native spatial contexts104-106. In this method, multiple fluorescently 
labeled varied oligonucleotide probed are hybridized to its target gene and imaged under a 
fluorescence microscope as diffraction-limited spots that are counted to determine 
expression levels in single cells. smFISH can be applied in tissue sections, is quantitative, 
and has nearly 100 percent detection sensitivity. However, multiplexing capability is 
limited due to spectral overlap of commonly available organic fluorophores. 
To enable multiplexed transcripts quantification in situ in single-cell, combinatorial 
barcoding that used optical super-resolution microscopy (SRM) and combinatorial labeling 
has been introduced13. In this method, they used the smFISH-based approach with two 
different barcoding strategies: spectral and spatial. In spatial barcoding, superresolution 
microscopy is used to resolve fluorophores targeting different segments along the length 
of an RNA. In spectral barcoding, a specific combination of fluorophores is used in the 
probes13, 107. Spectral barcoding is less technically demanding and more robust, while 
spatial barcoding allows higher multiplexing. However, this platform has limited 
multiplexing capacities. 
Recently, the sequential hybridization technique has been introduced14, where it 
utilized temporal barcoding. In this method, same RNA molecules are repeatedly labeled 
in a predefined color sequence with multiple cycles of smFISH hybridization and stripping. 
With temporal barcoding, a number of nucleic acids can be profiled as the number of 
fluorophores to the power of the number of cycles, as long as individual molecules are 
distinguishable. Temporal barcodes are sensitive to false negative hybridizations, and 
tissue movement between the cycles can lead to one barcode to another or invalid barcodes. 
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Additionally, Sequential hybridization utilizes DNase to degrade probe to remove the 
signal, which has limited efficiency and time-consuming. 
To cover the entire transcriptome, multiplexed error-robust fluorescence in situ 
hybridization (MERFISH) has been introduced10. It uses a modified Hamming code 
(originally used for error-free telecommunication) to detect each gene and correct errors in 
the temporal barcode. MERFISH utilizes an indirect labeling approach in which non-
labeled oligonucleotides pre-decoding probes are hybridized to all target genes and have 
two non-binding tails to which fluorescent decoding probes are hybridized. It has identified 
130 transcripts reliably and demonstrated with error-robust coding. MERFISH identified 
an impressive 985 transcripts when error-correcting barcodes are omitted, although 
detection efficiency decreased to around 25%. MERFISH utilized photobleaching to erase 
signals between cycles, which is very time-consuming. Recently, it adapted disulfide 
cleavage108 to make the process faster and overcome tissue autofluorescence tissue clearing 
techniques109 were used to cross-link mRNA to a scaffold. One current limitation of 
MERFISH, it can detect only large transcripts (> 3 Kb) as a large number of pre-decoding 
probes has to be hybridized on the target gene. 
A recent advancement in multiplexed RNA FISH is reiterative hybridizations4, 110. 
The simplicity of the approach and less technically demanding process make it an attractive 
candidate. Such methods include photobleaching to erase signals between cycles110 and 
probe stripping by formamide4. Photobleaching has long assay time and low sample 
throughput as it removes fluorescence signals in individual areas sequentially. Formamide 
strips all the probes including oligonucleotide library targeting to RNA. As a result, 
expensive oligonucleotide probes have to hybridize again, which makes the process time-
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consuming and less cost-effective. Additionally, the large pool of oligonucleotide probe 
removal from the thick tissue by diffusion can be inefficient and slow, limiting its 
application for intact tissue analysis. 
1.3.4 Biomedical applications 
Single-cell RNA sequencing can accelerate our understanding of different cell types that 
make up the brain. Linking molecular cell types to physiological, morphological and 
behavioral will help us understanding brain development, function, and disease. Emerging 
spatial transcriptomics will fill this gap by localizing molecularly distinct cell type in 
tissues, with simultaneous detection of morphology, activity or connectivity. Advances in 
single-cell transcriptomics will help us catalog complete inventory of molecularly defined 
cell types in mouse and the human brain, and efforts are underway through the Human Cell 
Atlas initiative, the NIH BRAIN initiative, and the European Human Brain Project111. 
Combination of single-cell RNA sequencing and clustering algorithms will give us 
insights into the molecular classification of different cell types. This will lead to identifying 
distinct combinatorial gene panels, which are sufficient to discriminate between different 
cell types (Figure 1.4.2). Multiplexed smRNA FISH can be applied to those marker gene 
panels to map spatial locations, composition, and function of different transcriptomic cell 
types112. Additionally, perturbation of those marker gene panels by CRISPR-cas9 and or 
small molecule may help us to understand cellular heterogeneity in diseases better. 
1.3.5 Summary and outlook 
Recent developments in enormously parallel single-cell RNA sequencing and sophisticated 
computational approaches are catalyzing our understanding of complex biological systems. 
For example, single-cell RNA sequencing can characterize the complex interactions, 
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networks, and responses of immune cells yield distinct cellular ecosystem comprised of 
multiple cell types113. However, making cell suspensions for certain tissue types will 
require different procedures. Additionally, storage of materials could pose a challenge. 
Moreover, when studying of hundreds of thousands of cells, the cost of sequencing is still 
prohibitive even at a shallow depth. 
The precise location of biomolecules in cell and cells in a tissue is essential for 
effective biomolecule-biomolecule and cell-cell interactions, which can determine cell 
functions and fates. For example, to study how neurons in brains develop and maintain 
their molecularly and morphologically distinct compartments–such as axons, dendrites, 
cell bodies, and synapses–we need to quantify multiple RNAs and protein in different 
compartments at its original locations. Additionally, to study signal transmission between 
presynaptic and postsynaptic neurons, in situ analysis of biomolecules in communicating 
neurons and interacting synapses can provide valuable insights. Moreover, it has been 
established stem cells in the niche can determine their fates114 and biomolecules can 
mislocate in cancer115. Spatial transcriptomics has a clear potential to classify 
transcriptional cell types and map their spatial locations in tissues, creating censuses of cell 
types and their development trajectories. However, multiplexing is limited due to limited 
optical and physical space inside the cells. When multiple transcripts are imaged 
simultaneously using combinatorial barcodes, the optical space gets crowded. Barcodes 
become difficult to read when multiplexing is increased, molecules start to overlap. To 
overcome the physical space inside the cells, expansion microscopy can be used, so that 
transcript belongs to same diffraction limited spots can be pulled apart116, 117. Multiplexing 
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smRNA FISH with expansion microscopy has been demonstrated. Nevertheless, expansion 
microscopy increases the volume of the cells, which limits the throughput of imaging. 
Although smRNA FISH is a routine laboratory technique to investigate the 
transcriptional profile of single cells in its native environment, applications of smRNA 
FISH beyond cell culture has proven to be challenging. Several factors limit the use of this 
technique in thick tissue: first, tissue auto-fluorescence can render some parts of the image 
obscure; second, the thickness of the sample reduces the permeability of fluorescent 
probes, which results in low hybridization efficiencies; and third, the thickness of tissue 
increases light-scattering. Sudan Black dye can be used to quench partially tissue auto-
fluorescence. Combining hybridization chain reaction (HCR) with smRNA FISH can 
improve the signal-to-noise ratio118, 119. Alternatively, hydrogel tissue-clearing 
technique120, 121 can be applied on the thick tissue and imaged either with confocal imaging 
or light sheet microscopy to get rid of out of focus signals. 
The computational data analysis for spatial transcriptomics remains in its infancy, 
relying on a human to interpret the images. To realize the full potential of this approach, 
an automated workflow is needed, transforming the image files into a computable data. 
Although there are efficient algorithms for discovering spatial objects such as cells, nuclei, 
vessels, and tissue borders for dispersed cells in culture, tissue sections are much more 
challenging. Neural networking has been promising developments for the discovery of 
complex higher-order feature detection and classification, such as cell-cell interaction 
motifs, spatial localization of mRNAs, or transportation into axons. Deep learning has 
immense impacts in other areas of genomics, because of its unsupervised feature 
detection122, 123. 
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Converging of imaging technologies with high-throughput sequencing will 
quantify thousands of different transcripts in cells and tissues while preserving spatial 
information. Spatial transcriptomics will have profound impacts on many fields of study. 
It will reveal the spatial architecture of complex transcriptional networks in healthy and 
diseased tissue and organs, as well as subcellular RNA localizations and their functional 
implications. Emerging spatially proteomics, genomics and epigenomics will produce a 
comprehensive system-level portrait of thousands of different molecular states–including 
RNA and protein abundance and modifications, 3D genome organization, DNA and 
chromatin modifications, DNA sequence variation and copy number–at various locations 
within cells and tissues11. It will enable us a system-level understanding of how complex 
multicellular organisms function by the coordinated action of millions of molecules 
simultaneously. 
1.4 Figures 
 
Figure 1.4.1 (A) Comprehensive protein profiling in individual cells of a biological 
sample. (B) Based on their protein expression profiles, cells are clustered into subgroups. 
(C) Expression correlation of the protein pairs. Each spot corresponds to one cell with 
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protein expression levels in the x and y axes. (D) A signaling network with activating and 
inhibitory protein interactions. 
 
	
	
Figure 1.4.2 Mapping spatial distribution of transcriptomic cell types. (A) Single-cell 
transcription involves making single cell suspension following tissue dissociation. 
Different cell types can be identified using the clustering algorithms. Combinatorial 
distinct marker genes will discriminate different transcriptome cell types. Multiplexes 
mRNA FISH can be applied on those marker gene panels to quantify different cell types 
with its spatial location. (B) Spatial phenotype distribution can be associated with human 
disease. Reproduced with permission from Ref112. 
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CHAPTER 2 
HIGHLY MULTIPLEXED SINGLE-CELL IN SITU PROTEIN ANALYSIS WITH 
CLEAVABLE FLUORESCENT ANTIBODIES 
2.1 Abstract 
Limitations on the number of proteins that can be quantified in single cells in situ impede 
advances in our deep understanding of normal cell physiology and disease pathogenesis. 
Herein, we present a highly multiplexed single-cell in situ protein analysis approach that 
is based on chemically cleavable fluorescent antibodies. In this method, antibodies tethered 
to fluorophores through a novel azide-based cleavable linker are utilized to detect their 
protein targets. After fluorescence imaging and data storage, the fluorophores coupled to 
the antibodies are efficiently cleaved without loss of protein target antigenicity. Upon 
continuous cycles of target recognition, fluorescence imaging, and fluorophore cleavage, 
this approach has the potential to quantify over 100 different proteins in individual cells at 
optical resolution. This single-cell in situ protein profiling technology will have wide 
applications in signaling network analysis, molecular diagnosis, and cellular targeted 
therapies. 
2.1 Introduction 
The ability to profile proteins comprehensively in single cells in situ is crucial for our 
understanding of the organization, regulation, and function of heterogeneous biological 
systems, such as solid tumors, brain tissues, and developing embryos. Mass-spectrometry1 
and microarray2-based proteomic technologies are powerful tools for comprehensive 
protein profiling. Nonetheless, as they are carried out on pools of cells, these technologies 
mask the spatial complexity of proteins and their expression variations in a population. 
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Fluorescence microscopy has been widely used to quantify the positions and abundances 
of proteins in individual cells. However, owing to the spectral overlap of commonly 
available organic fluorophores3-5 and fluorescent proteins6, 7, the multiplexing capacity of 
fluorescence-imaging-based approaches is limited. 
To enable multiplexed single-cell protein analysis, a number of methods have been 
explored. For example, mass cytometry8 and single-cell barcode chips9-11 have been 
developed for comprehensive protein profiling in individual cells. However, these 
approaches are unable to quantify the location of proteins. Cyclic immunofluorescence 
methods, which apply photobleaching12, chemical reagents13, 14, or DNA displacement 
reactions15, 16 to erase fluorescence signals, have also been investigated. Nonetheless, the 
photobleaching process is highly time-consuming, and limits the number of cells that can 
be analyzed in a sample17, harsh chemical reagents often result in specimen degradation 
and interfere with subsequent cycles of staining, and mis-hybridization between different 
DNA complexes along with non-specific binding between DNA complexes and 
endogenous biomolecules may lead to increased background. Recently, mass cytometry18 
imaging and ion beam imaging19 with metal-isotope-labeled antibodies have been 
developed for multiplexed protein profiling. However, these mass spectrometry-based 
approaches have limited imaging resolution18 or imaging speed and sample throughput19. 
Herein, we report a highly multiplexed single-cell in situ protein analysis approach 
with cleavable fluorescent antibodies (CFAs), which might be able to quantify over 100 
different proteins in individual cells at optical resolution. As illustrated in Figure 2.4.1, this 
CFA-based in situ protein profiling technology is based on three major steps in each 
immunofluorescence cycle. First, different antibodies tethered to various fluorophores via 
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the same cleavable linker are used to stain their corresponding protein targets. In the second 
step, fluorescence images are acquired in each fluorescence channel to generate 
quantitative protein expression profiles. Finally, all of the different fluorophores attached 
to the antibodies are simultaneously removed by cleavage of the linker, which enables the 
initiation of the next immunofluorescence cycle. Through continuous cycles of target 
binding, fluorescence imaging, and fluorophore cleavage, comprehensive protein profiling 
can be achieved. 
2.3 Results and discussion 
A critical requirement for the success of this CFA-based protein profiling technology was 
the development of a linker that can be efficiently cleaved within the cellular environment 
and without loss of protein target antigenicity. A previously reported azide-based linker 
can be efficiently cleaved with the mild reducing reagent tris(2-carboxyethyl)phosphine 
(TCEP)20, 21. However, some properties of the reported linker limit its application in the 
CFA-based protein profiling approach. For example, the high cleavage temperature of 65 
°C can lead to specimen degradation after repeated TCEP treatment. Furthermore, the 
relatively large size of the linker may interfere with the binding specificity and affinity of 
the antibodies. Moreover, it is unknown whether the high cleavage efficiency obtained in 
pure TCEP solution will be maintained within cellular environments. Finally, it remains 
undetermined whether TCEP treatment will result in the loss of protein target antigenicity 
in fixed cells. 
To overcome the limitations of the existing cleavable linker and test the hypothesis 
of applying CFAs for comprehensive protein profiling, we designed and synthesized a new 
azide-based cleavable linker (Figure 2.4.2A). A more strongly electron-donating -
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CH2CH2R group was used to replace the -CH2OAr group in the reported linker on one side 
of the cleavage functional group -OCH(N3)-. As a result, the stability of the cleavage 
intermediate ROCH(NH2)R’ (Figure 2.4.3) is decreased21, and the cleavage rate is 
increased (Figure 2.4.4) so that the temperature required for cleavage is reduced. 
Furthermore, this new linker has a much smaller size than the previously reported cleavable 
linker and most organic fluorophores. Thus, CFAs with fluorophores attached to the 
antibodies via this small linker should give binding specificities and affinities similar to 
those of conventional fluorescent antibodies.  
This new azide-based cleavable linker was obtained in three steps in an overall 
yield of 34% (Figure 2.4.2A) while the synthesis of the previously reported linker required 
six steps with an overall yield of 18%21. Subsequently, fluorescein (Scheme 2.5.1), 
carboxytetramethylrhodamine (TAMRA) (Scheme 2.5.2), and Cy5 N-hydroxysuccinimide 
(NHS) ester (Scheme 2.5.3) were coupled to the cleavable linker. The generated products 
were converted into the corresponding NHS esters and then coupled with lysine residues 
on the antibodies to afford Ab-N3-Fluorescein, Ab-N3-TAMRA, and Ab-N3-Cy5 (Figure 
2.4.2B).  
To demonstrate the feasibility of applying CFAs for multiplexed single-cell in situ 
protein analysis, we labeled Ki67 or a-tubulin in HeLa cells with Ab-N3-Fluroscein (Figure 
2.4.5A), Ab-N3-TAMRA (Figure 2.4.5D), or Ab-N3-Cy5 (Figure 2.4.5G). To optimize the 
fluorophore cleavage efficiency within cells at 37 °C, we evaluated various reaction 
conditions, including different TCEP concentrations (Figure 2.4.6), different pH values 
(Figure 2.4.7), and various reaction times (Figure 2.4.8). Among these conditions, 100 mm 
TCEP, pH 9.5, and a reaction time of 30 min are the minimum requirements to achieve 
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maximum cleavage efficiency. Thus, these cleavage conditions were applied to remove the 
fluorescence signals from labeled Ki67 or a-tubulin. After fluorophore cleavage, the 
fluorescence signals had been erased almost completely (Figure 2.4.5B, E, H). The on/off 
ratios between the signals before and after the TCEP treatment were over 20:1 (Figure 
2.4.5C, F, I). We performed control experiments by staining Ki67 and a-tubulin with 
conventional fluorescent antibodies (Figure 2.4.9). The obtained protein distribution 
patterns and expression levels are similar to those generated by CFA. Upon incubation with 
100 mm TCEP (pH 9.5) for 30 min, the fluorescence intensities remained largely 
unchanged, with an on/off ratio of < 1.5 :1 (Figure 2.4.9). These results indicate that CFAs 
with the small azide-based cleavable linker can stain protein targets with similar binding 
specificities and affinities to standard fluorescent antibodies, and the generated 
immunofluorescence signals can be efficiently erased using TCEP by cleavage of the 
fluorophores attached to the antibodies. 
Most of the antibodies applied in immunofluorescence have linear epitopes whose 
primary amino acid sequences are used to identify antigens by antibodies. The TCEP 
treatment does not alter the chemical structures or sequences of these epitopes22. Thus, the 
antigenicity of the protein targets will be preserved after the TCEP treatment. To 
demonstrate this, we incubated HeLa cells with (Figure 2.4.5J) and without (Figure 2.4.5K) 
TCEP at 37 °C for 24 h, followed by a-tubulin labeling. The labeling specificity and the 
fluorescence signal intensity (Figure 2.4.5L) are similar under both conditions, suggesting 
that the antigenicity of protein targets is not altered by the TCEP treatment. 
To further assess the effectiveness of our approach, we labeled twelve different 
proteins in single cells in situ using CFAs. As shown above, with antibodies coupled to 
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various cleavable fluorophores, at least three distinct proteins can be quantified at the same 
time in one immunofluorescence cycle. However, to demonstrate the multicycle potential 
of this approach, we labeled one protein per cycle using N3-TAMRA conjugated primary 
antibodies. Through reiterative cycles of staining, imaging, and cleavage, p-4E-BP1, pan 
cytokeratin, p-Akt (T308), p-Akt (S473), p-p44/42 MAPK, EGF receptor, c-erbB2, p53, 
Ki67, Ezh2, vimentin, and histone H4 were unambiguously detected with the 
corresponding Ab-N3- TAMRA in the same set of cells (Figure 2.4.10A–L). In each cycle, 
DAPI-stained nuclei were also imaged, which provided fiducial points to align and overlay 
the images generated in reiterative immunofluorescence cycles (Figure 2.4.10M). In this 
way, protein co-localization can be studied at the pixel level13. To further evaluate the 
alignment accuracy, we stained Ki67 in two consecutive immunofluorescence cycles using 
Ab-N3- TAMRA. After image alignment and overlay, the Ki67 proteins stained in the two 
cycles completely co-localize with each other (Figure 2.4.11), suggesting that our approach 
enables the study of protein co-localization at optical resolution.  
We also performed conventional immunofluorescence experiments to stain these 
twelve protein targets in twelve different sets of cells with TAMRA conjugated primary 
antibodies (Figure 2.4.12). The distribution patterns of the protein targets obtained by our 
CFA-based approach closely resemble those obtained by conventional 
immunofluorescence assays. To assess the accuracy of the gene expression levels obtained 
by our approach, we compared the mean expression levels of the twelve protein targets per 
cell measured by our CFA-based approach and a conventional immunofluorescence assay. 
For all twelve protein targets with various expression levels, the results obtained using the 
two methods are consistent with each other (Figure 2.4.13A). Comparison of the two sets 
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of results yields an R2 value of 0.96 with a slope of 1.11 (Figure 2.4.13B). These results 
suggest that the CFA-based approach enables quantitative and comprehensive protein 
profiling in single cells in situ. 
With the multiplexed single-cell protein expression results, we studied protein 
expression heterogeneity in genetically identical cells. The expression distribution for 
almost all of the measured proteins includes a basal state of low expression and a long tail 
of high expression (Figure 2.4.14A). This mode suggests that these proteins are generated 
in bursts, rather than at a constant rate23. We also examined the pairwise expression 
covariation of the twelve measured proteins, and calculated the corresponding correlation 
coefficient of each protein pair (Figure 2.4.14B). Applying a hierarchical clustering 
approach (Figure 2.4.14B), we identified a group of eight proteins with tightly correlated 
expression patterns. Indeed, all of the eight proteins in the identified group are involved in 
ERBB receptor signaling24 or cell proliferation25, 26 related pathways. 
In summary, we have designed and synthesized cleavable fluorescent antibodies 
and applied them in multiplexed single-cell in situ protein profiling. The number of 
proteins that can be detected in individual cells using the CFA-based approach depends on 
two factors: the number of immunofluorescence cycles and the number of proteins 
analyzed in each cycle. TCEP can efficiently remove the fluorophores within 30 min while 
the antigenicity of the protein targets was preserved after incubation with TCEP for at least 
24 h. This suggests that we can further increase the cycling number significantly. With 
classical fluorophores of different colors, four or five different protein targets can be 
quantified in each immunofluorescence cycle. Furthermore, fluorophores with 
multispectral properties13 will allow for more proteins to be analyzed in one cycle using 
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hyperspectral imaging techniques. Therefore, we envision that this CFA-based approach 
has the potential to detect over 100 protein targets in single cells in situ. Furthermore, the 
chemically cleavable fluorophores developed here can also be applied in other areas 
beyond protein quantification, such as DNA or RNA in situ hybridization27 and metabolic 
analysis. These extended applications provide a highly multiplexed imaging platform that 
integrates DNA, RNA, protein, and metabolic analysis at optical resolution in single cells, 
which will provide new insight into systems biology, cell heterogeneity, cell signaling 
regulation, molecular diagnosis, and cellular targeted therapy. 
2.4 Figures 
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Figure 2.4.1 Highly multiplexed single-cell in situ protein analysis with cleavable 
fluorescent antibodies. Protein targets are stained with antibodies tethered to fluorophores 
via a cleavable linker. After imaging, the fluorophores are removed by cleavage of the 
linker. Through cycles of staining, imaging, and cleavage, a large number of different 
protein targets can be detected in individual cells in situ. 
 
 
Figure 2.4.2 A) Synthesis of the azide-based cleavable linker. Reagents and conditions: i) 
diethyl ether, 0 °C to RT, 30 min, 97%; ii) (CH3)3SiN3, SnCl4, CH2Cl2, 78 °C to RT, 15 h, 
44 %; iii) piperidine, CH2Cl2, RT, 30 min, 80 %. B) Structures of the cleavable fluorescent 
antibodies Ab-N3-Fluorescein, Ab-N3-TAMRA, and Ab-N3-Cy5. 
 
 
Figure 2.4.3 Mechanisms to cleave fluorophores from cleavable fluorescent antibodies. 
The azide group on the cleavable linker is reduced by TCEP via the Staudinger reaction. 
The following hydrolysis breaks the linker and separates the fluorophores and antibodies28.  
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Figure 2.4.4 Comparison of the cleavage reaction rates of the linker described here and the 
reported linker20. Representative absorption spectra of (A) cleavable Cy5 labeled antibody 
with the new linker, and its cleavage products generated by incubation with 20 mM TCEP 
for (B) 15, (C) 30, (D) 45 and (E) 60 min. Representative absorption spectra of (F) 
cleavable Cy5 labeled antibody with the reported linker, and its cleavage products 
generated by incubation with 20 mM TCEP for (G) 15, (H) 30, (I) 45 and (J) 60 min. (K) 
The cleavage reaction yields of the cleavable Cy5 labeled antibodies with the two 
respective linkers for different reaction time. 
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Figure 2.4.5 A) Ki67 is detected with Ab-N3-Fluorescein. B) Fluorescein is cleaved by 
TCEP. C) Fluorescence intensity profiles of the areas indicated by red and green lines in 
(A) and (B). D) a-Tubulin is detected with Ab-N3-TAMRA. E) TAMRA is cleaved by 
TCEP. F) Fluorescence intensity profiles of the areas indicated by red and green lines in 
(D) and (E). G) Ki67 is detected with Ab-N3-Cy5. H) Cy5 is cleaved by TCEP. I) 
Fluorescence intensity profiles of the areas indicated by red and green lines in (G) and (H). 
J) After incubation with TCEP for 24 h, a-tubulin is detected with Ab-N3-TAMRA. K) 
Without incubation with TCEP, a-tubulin is directly detected with Ab-N3-TAMRA. L) 
Fluorescence intensity of the a-tubulin staining in (J) and (K) (n = 30). Scale bars: 20 µm.  
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Figure 2.4.6 (A) Vimentin is detected with Ab-N3-Cy5 and (B) subsequently incubated 
with 1 mM TCEP. (C) Fluorescence intensity profile corresponding to the red line and 
green line positions in (A) and (B). (D) Vimentin is detected with Ab-N3-Cy5 and (E) 
subsequently incubated with 10 mM TCEP. (F) Fluorescence intensity profile 
corresponding to the red line and green line positions in (D) and (E). (G) Vimentin is 
detected with Ab-N3-Cy5 and (H) subsequently incubated with 100 mM TCEP. (I) 
Fluorescence intensity profile corresponding to the red line and green line positions in (G) 
and (H). (J) Vimentin is detected with Ab-N3-Cy5 and (K) subsequently incubated with 1 
M TCEP. (L) Fluorescence intensity profile corresponding to the red line and green line 
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positions in (J) and (K). (M) Fluorophore cleavage efficiency with TCEP at different 
concentrations (n = 30 positions). Scale bars, 20 µm. 
 
 
 
Figure 2.4.7 (A) Vimentin is detected with Ab-N3-Cy5 and (B) subsequently incubated 
with 100 mM TCEP (pH = 7.5). (C) Fluorescence intensity profile corresponding to the 
red line and green line positions in (A) and (B). (D) Vimentin is detected with Ab-N3-Cy5 
and (E) subsequently incubated with 100 mM TCEP (pH = 8.5). (F) Fluorescence intensity 
profile corresponding to the red line and green line positions in (D) and (E). (G) Vimentin 
is detected with Ab-N3-Cy5 and (H) subsequently incubated with 100 mM TCEP (pH = 
9.5). (I) Fluorescence intensity profile corresponding to the red line and green line positions 
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in (G) and (H). (J) Vimentin is detected with Ab-N3-Cy5 and (K) subsequently incubated 
with 100 mM TCEP (pH = 10.5). (L) Fluorescence intensity profile corresponding to the 
red line and green line positions in (J) and (K). (M) Fluorophore cleavage efficiency with 
100 mM TCEP at different pH (n = 30 positions). Scale bars, 20 µm.  
 
 
Figure 2.4.8 (A) Vimentin is detected with Ab-N3-Cy5 and (B) subsequently incubated 
with 100 mM TCEP (pH = 9.5) for 5 min. (C) Fluorescence intensity profile corresponding 
to the red line and green line positions in (A) and (B). (D) Vimentin is detected with Ab-
N3-Cy5 and (E) subsequently incubated with 100 mM TCEP (pH = 9.5) for 15 min. (F) 
Fluorescence intensity profile corresponding to the red line and green line positions in (D) 
and (E). (G) Vimentin is detected with Ab-N3-Cy5 and (H) subsequently incubated with 
100 mM TCEP (pH = 9.5) for 30 min. (I) Fluorescence intensity profile corresponding to 
the red line and green line positions in (G) and (H). (J) Vimentin is detected with Ab-N3-
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Cy5 and (K) subsequently incubated with 100 mM TCEP (pH = 9.5) for 1 hr. (L) 
Fluorescence intensity profile corresponding to the red line and green line positions in (J) 
and (K). (M) Fluorophore cleavage efficiency with 100 mM TCEP (pH = 9.5) for different 
time (n = 30 positions). Scale bars, 20 µm. 
 
 
Figure 2.4.9 (A) Ki67 is detected with Fluorescein conjugated antibodies and (B) 
subsequently incubated with TCEP. (C) Fluorescence intensity profile corresponding to the 
red line and green line positions in (A) and (B). (D) α-Tubulin is detected with TAMRA 
conjugated antibodies, and (E) subsequently incubated with TCEP. (F) Fluorescence 
intensity profile corresponding to the red line and green line positions in (D) and (E). (G) 
Ki67 is detected with Cy5 conjugated antibodies and (H) subsequently incubated with 
TCEP. (I) Fluorescence intensity profile corresponding to the red line and green line 
positions in (G) and (H). Scale bars, 20 µm.  
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Figure 2.4.10 A) p-4E-BP1, B) pan cytokeratin, C) p-Akt (T308), D) p-Akt (S473), E) p-
p44/42 MAPK, F) EGF receptor, G) c-erbB2, H) p53, I) Ki67, J) Ezh2, K) vimentin, and 
L) histone H4 were detected with the corresponding Ab-N3-TAMRA in the same set of 
cells. M) Digital overlay of (A)–(L). Scale bars: 60 µm. 
 
 
Figure 2.4.11 Image alignment and overlay with DAPI-stained nuclei (blue) as fiducial 
points. (A) Ki67 is stained with Ab-N3-TAMRA (green) and (B) subsequently incubated 
with TCEP. (C) Ki67 is re-stained with Ab-N3-TAMRA (red). (D) Digital alignment and 
overlay of A and C. Scale bars, 3 µm. 
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Figure 2.4.12 A) p-4E-BP1, (B) Pan Cytokeratin, (C) p-Akt (T308), (D) p-Akt (S473), (E) 
p-p44/42 MAPK, (F) EGF receptor, (G) c-erbB2, (H) p53, (I) Ki67, (J) Ezh2, (K) Vimentin 
and (L) Histone H4 are detected with TAMRA labeled antibodies in different cells. Scale 
bars, 60 µm. 
 
 
Figure 2.4.13 (A) Mean expression level per cell (n = 30 cells) of 12 different proteins 
measured by immunofluorescence with CFA and conventional immunofluorescence. (B) 
Comparison of the results obtained by immunofluorescence with CFA and conventional 
immunofluorescence yields R2 = 0.96 with a slope of 1.11. 
 
 
 
 
 
 
 
 
	 52	
 
 
Figure 2.4.14 Protein expression heterogeneity and correlation. (A) Histograms of the 
expression level per cell of the 12 measured proteins. (B) Correlation of the expression 
levels of the 12 measured proteins and the hierarchical clustering tree. The protein names 
are shown in the diagonal. The upper triangle displays the expression correlation 
coefficient of each protein pair. And the lower triangle shows the color corresponding to 
the correlation coefficient. A group of proteins identified by a specific threshold on the 
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cluster tree (dashed line) is indicated by the black box in the matrix and the red lines on the 
tree. 
 
 
Figure 2.4.15 Representative light path in an epifluorescence microscope. Dichroic mirror 
controls both excitation and emission wavelength. It reflects the excitation light (shorter 
wavelength) onto the specimen and passes the resulting emission light (longer wavelength) 
through the emission filter and on to the detector. 
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2.5 Schemes 
 
 
Schemes 2.5.1 Synthesis of Ab-N3-Fluorescein. Reagents and conditions: (i) DMF/1 M 
NaHCO3, rt, 6 h. (ii) N, N'- disuccinimidyl carbonate, Et3N, DMF, rt, 10 h. (iii) antibodies, 
0.1 M NaHCO3, rt, 15 min. 
 
 
Schemes 2.5.2 Synthesis of Ab-N3-TAMRA. Reagents and conditions: (i) DMF/1 M 
NaHCO3, rt, 6 h. (ii) N, N'- disuccinimidyl carbonate, Et3N, DMF, rt, 10 h. (iii) antibodies, 
0.1 M NaHCO3, rt, 15 min. 
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Schemes 2.5.3 Synthesis of Ab-N3-Cy5. Reagents and conditions: (i) DMF/1 M NaHCO3, 
rt, 6 h. (ii) N, N'- disuccinimidyl carbonate, Et3N, DMF, rt, 10 h. (iii) antibodies, 0.1 M 
NaHCO3, rt, 15 min. 
 
 
Schemes 2.5.4 Synthesis of cleavable Cy5 conjugated antibodies with the reported linker20. 
Reagents and conditions: (i) N, N'- disuccinimidyl carbonate, Et3N, DMF, rt, 10 h. (ii) 
antibodies, 0.1 M NaHCO3, rt, 15 min. 
 
2.6 Methods 
2.6.1 General Information 
Chemicals and solvents were purchased from Sigma-Aldrich or TCI America and were 
used directly without further purification, unless otherwise noted. Bioreagents were 
purchased from Invitrogen, unless otherwise indicated. 1H-NMR and 13C-NMR were taken 
on Varian Innova 400 MHz NMR spectrometers. Chemical shifts are reported in parts 
permillion (ppm) downfield from tetramethylsilane (TMS). Data are reported as follows: 
chemicalshift, multiplicity: singlet (s), doublet (d), triplet (t), multiplet (m), coupling 
constants J in Hz, and integration. HRMS was performed by the Arizona State University 
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mass spectrometry facility. Absorption spectra were obtained on a NanoVue Plus 
spectrometer. 
2.6.2 Synthesis of the azidoethyl linker  
(9H-fluoren-9-yl)methyl (2-(1,3-dioxolan-2-yl)ethyl)carbamate (1): A stirred solution 
of 9-fluorenylmethyl chloroformate (6.6 g; 25.6 mmol) in 40 ml of ether was cooled in an 
ice bath. Commercially available 2-(aminoethyl)-1,3-dioxolane (2 g; 17.0 mmol) was 
added slowly. The reaction mixture was stirred at 0°C for 10 minutes and then at room 
temperature for 30 minutes. After evaporation of ether from the reaction mixture 
completely, the residue was purified by flash column chromatography using ethyl 
acetate/hexane (1:2 to 1:1) to afford compound 1 as a white solid (5.67 g; 97% yield). 1H 
NMR (400 MHz, CDCl3) δ 7.75 (d, J = 7.5 Hz, 2H), 7.62 (d, J = 7.5 Hz, 2H), 7.39 (t, J = 
7.5 Hz, 2H), 7.31 (d, J = 7.5 Hz, 2H), 4.90 (t, J = 4.5 Hz, 1H), 4.41 (d, J = 7.1 Hz, 2H), 
4.24 (t, J = 8 Hz, 1H), 3.96-3.88 (m, 2H), 3.83-3.75 (m, 2H), 3.38 (t, J = 6.2 Hz, 2H), 1.93- 
1.88 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 156.43, 144.10, 141.31, 127.67, 127.05, 
125.13, 119.99, 103.31, 66.56, 64.88, 47.33, 36.40, 33.36; HRMS (ESI, m/z) calcd for 
C20H21NO4Na [(M+Na)+]: 362.1368, found: 362.1360. 
(9H-fluoren-9-yl)methyl (3-azido-3-(2-hydroxyethoxy)propyl)carbamate (2): A 
stirred solution of compound 1(1.0 g; 2.95 mmol) in 20 ml CH2Cl2 was cooled at -78 °C in 
a dry ice/acetone bath under nitrogen atmosphere. To this solution azidotrimehtylsilane 
(0.8 ml; 6.11 mmol) and Tin (IV) chloride (1 M solution in CH2Cl2; 150 µl) were added. 
Then the reaction mixture was warmed to room temperature over 15 hours. After adding 
CH2Cl2 (100 ml) to the reaction mixture, the organic layer was washed with water and 
dried over anhydrous Na2SO4. After evaporation of CH2Cl2 from the reaction mixture, the 
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residue was purified by flash column chromatography using ethyl acetate/hexane (1:1) to 
afford compound 2 as a colorless liquid (495 mg; 44% yield). 1H NMR (400 MHz, CDCl3) 
δ 7.75 (d, J = 7.5 Hz, 2H), 7.57 (d, J = 7.4 Hz, 2H), 7.39 (td, J = 7.5, 1.1 Hz, 2H), 7.30 (td, 
J = 7.4, 1.2 Hz, 2H), 4.48 (t, J = 6 Hz, 1H), 4.43 (d, J = 4 Hz, 2H), 4.19 (t, J = 6.6 Hz, 1H), 
3.91-3.87 (m, 1H), 3.78-3.69 (m, 2H), 3.61- 3.56 (m, 1H), 3.49-3.40 (m, 1H), 3.29-3.20 
(m, 1H), 1.95- 1.89 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 156.60, 143.87, 141.31, 
127.68, 127.04, 124.93, 119.95, 91.01, 70.74, 66.46, 61.53, 47.26, 36.88, 34.73; HRMS 
(APCI, m/z) calcd for C20H23N2O4 [(M-N2+H)+]: 355.1658, found: 355.1648.  
2-(3-amino-1-azidopropoxy)ethanol (3): Piperidine (0.3 ml; 3.03 mmol) was added to a 
stirred solution of compound 2 (300mg; 0.79 mmol) in 3 ml CH2Cl2 . The reaction mixture 
was stirred at room temperature for 30 minutes. After completion of the reaction most of 
the solvent and piperidine were dried under vacuum. The residue was purified by flash 
column chromatography using ethyl acetate/hexane (1:1) and then 5% NH4OH in 
methanol/dichloromethane (1:1) to afford compound 3 as a brown oil (100 mg; 80% yield). 
1H NMR (400 MHz, CD3OD) δ 4.66 (t, J = 5.9 Hz, 1H), 3.81-3.76 (m, 1H), 3.65- 3.52 (m, 
3H), 2.81 (t, J = 6.7 Hz, 2H), 1.91-1.86 (m, 2H); 13C NMR (100 MHz, CD3OD) δ 91.28, 
70.50, 60.50, 36.55, 35.27; HRMS (FAB, m/z) calcd for C5H13N4O2 [(M+H)+]: 161.1038, 
found: 161.1037. 
2.6.2 Synthesis of cleavable fluorescent antibodies  
Synthesis of Ab-N3-Fluorescein  
N3-Fluorescein (4): To a stirred solution of compound 3 (1 mg; 6.24 µmol) in anhydrous 
DMF (860 µl), 1 M NaHCO3 (100 µl) was added. Then the solution was stirred at room 
temperature for 5 minutes. Fluorescein NHS (N-hydroxysuccinimide) ester (1 mg; 2.11 
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µmol) in 40 µl of anhydrous DMF was added. The reaction mixture was stirred at room 
temperature for around 6 hours. After completion the reaction DMF was removed 
completely under vacuum. The crude product was purified by a preparative silica gel TLC 
plate by using CH3OH/CH2Cl2 (1:5) to afford 4 as a yellow solid. 1H NMR (400 MHz, 
CD3OD) δ 8.09-7.99 (m, 2H), 7.25 (d, J = 8 Hz, 1H), 6.76-6.68 (m, 2H), 6.62 (t, J = 1.9 
Hz, 2H), 6.53-6.47 (m, 2H), 4.66 (t, J = 6 Hz, 1H), 3.86-3.79 (m, 1H), 3.69-3.65 (m, 2H), 
3.54-3.50 (m, 1H), 3.59-3.55 (m, 2H), 2.02 (q, J = 6.5 Hz, 2H); HRMS (APCI, m/z) calcd 
for C26H23N4O8 [(M+H)+]: 519.1516, found: 519.1518.  
N3-Fluorescein NHS ester (5): To a stirred solution of compound 4 in anhydrous DMF 
(400 µl), DSC (N, N'-disuccinimidyl carbonate) (2 mg; 7.8 µmol) and triethylamine (1.1 
µl; 7.9 µmol) were added. The reaction mixture was stirred for 10 hours. After completion 
of the reaction, most of the DMF was removed under vacuum. After adding 30 ml of ethyl 
acetate, the organic layer was washed with water, dried over anhydrous Na2SO4 and 
evaporated under vacuum to afford compound 5 as a yellow solid. The product was used 
directly for antibody labeling.  
Ab-N3-Fluorescein (6): Antibodies (1mg/ml) were dissolved in 1× phosphate buffered 
saline (pH = 7.4) and compound 5 was dissolved in anhydrous DMF (500 µl). To a solution 
of an antibody (20 µl) were added sodium bicarbonate aqueous solution (1M, 2 µl) and 
compound 5 (1 µl). The reaction mixture was incubated at room temperature for 15 min. 
Subsequently, the N3-Fluorescein coupled antibodies were purified by size exclusion 
chromatography using Bio-Gel P-6 (Bio-Rad Laboratories). 
2.6.3 Synthesis of Ab-N3-TAMRA  
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N3-TAMRA (7): The preparation procedure was similar to the synthesis of compound 4. 
The crude product was purified by a preparative silica gel TLC plate by using 
CH3OH/CH2Cl2 (1:2) to afford 7 as a red solid. 1H NMR (400 MHz, CD3OD) δ 8.50 (s, 
1H), 8.06 (d, J = 6 Hz, 1H), 7.36 (d, J = 8 Hz, 1H), 7.25 (d, J = 9.5 Hz, 2H), 7.02 (dd, J = 
9.5, 2.4 Hz, 2H), 6.93 (d, J = 2.4 Hz, 2H), 4.75 (t, J = 6 Hz, 1H), 3.92- 3.89 (m, 2H), 3.76 
(t, J = 4.7 Hz, 2H), 3.28 (s, 12H), 3.13 (t, J = 6.7 Hz, 2H), 2.16- 2.08 (m, 2H); HRMS 
(APCI, m/z) calcd for C30H33N6O6 [(M+H)+]: 573.2462, found: 573.2456. 
N3-TAMRA NHS ester (8): The preparation procedure was similar to the synthesis of 
compound 5. After adding 30 ml of CH2Cl2, the organic layer was washed with water, dried 
over anhydrous Na2SO4 and evaporated under vacuum to afford compound 8 as a red solid. 
The product was used directly for antibody labeling. 
Ab-N3-TAMRA (9): The preparation procedure was similar to the synthesis of Ab-N3- 
Fluorescein.  
2.6.4 Synthesis of Ab-N3-Cy5  
N3-Cy5 (10): The preparation procedure was similar to the synthesis of compound 4. The 
crude product was purified by a preparative silica gel TLC plate by using CH3OH/CH2Cl2 
(1:3) to afford 10 as a blue solid. 1H NMR (400 MHz, CD3OD) δ 8.31-8.23 (m, 2H), 7.93 
(s, 1H), 7.84 (dd, J = 8.2, 3.6 Hz, 3H), 7.29 (dd, J = 8.3, 5.8 Hz, 2H), 6.63 (t, J = 12.4 Hz, 
1H), 6.29 (dd, J = 13.7, 8.5 Hz, 2H), 4.54 (t, J = 6.0 Hz, 1H), 4.19-4.06 (m, 5H), 3.79 (dt, 
J = 10.2, 4.3 Hz, 1H), 3.65 (dd, J = 5.3, 4.2 Hz, 2H), 3.59-3.53 (m, 1H), 2.15 (t, J = 7.2 Hz, 
2H), 1.86-1.76 (m, 4H), 1.66-1.61 (m, 3H), 1.42-1.24 (m, 12H), 0.92-0.83 (m, 5H); HRMS 
(ESI-, m/z) calcd for C38H49N6O9S2 [(M)-]: 797.3002, found: 797.3001.  
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N3-Cy5 NHS ester (11): The preparation procedure was similar to the synthesis of 
compound 5. The crude product was purified by a preparative silica gel TLC plate by using 
4% acetic acid in pure ethyl acetate to afford 11 as a blue solid. The product was used 
directly for antibody labeling.  
Ab-N3-Cy5 (12): The preparation procedure was similar to the synthesis of Ab-N3- 
Fluorescein.  
2.6.4 Comparison of cleavage rates  
Compound 13 was prepared according to the literature20. Compound 14 and cleavable Cy5 
conjugated antibodies 15 were obtained using the similar preparation procedure to the 
synthesis of N3-Cy5 NHS ester and Ab-N3-Cy5, respectively. Absorbance spectra of 
cleavable Cy5 conjugated antibodies 12 and 15 (Figure 2.5.4A, F) were obtained in 1× 
phosphate buffered saline (pH = 7.4).  
Cleavable Cy5 conjugated antibodies 12 and 15 were incubated with 20 mM TCEP 
at 37°C for 15, 30, 45 or 60 minutes, purified by size exclusion chromatography using Bio- 
Gel P-6, and characterized by absorption spectrometry (Figure 2.5.4B-E, G-J). The labeling 
number of the antibodies was determined by the equation:  
	
NL is the number of Cy5 moieties on each antibody molecule. A280 is absorption at 280 nm. 
ACy5 is absorption at 650 nm. eAb and eCy5 are the molar extinction coefficient of the 
antibody (203, 000 cm-1M-1) and Cy5 (250, 000 cm-1M-1), respectively. a is defended as 
the ratio of absorption of TAMRA at 280 nm and 650 nm (0.05). 
The cleavage reaction yields (Figure 2.5.4K) were calculated by the equation:  
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Y is the reaction yield. NLB and NLA are the labeling numbers before and after the 
cleavage reaction, respectively. Three independent experiments were conducted for each 
data point.  
2.6.5 Fluorophore cleavage in cells  
Cell culture  
HeLa CCL-2 cells (ATCC) were maintained in Dulbelcco’s modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 g/mL 
streptomycin in a humidified atmosphere at 37 °C with 5% CO2. Cells were plated on 
chambered coverglass (0.2 ml medium/chamber) (Thermo Scientific) and allowed to 
reach 60% confluency in 1-2 days.  
Cell fixation  
Cultured HeLa CCL-2 cells were fixed with 4% formaldehyde at 37 °C for 15 min, 
permeabilized with 0.2% (vol/vol) Triton X-100 at room temperature for 15 min, and 
subsequently blocked in 1X blocking buffer (1% (wt/vol) bovine serum albumin, 0.1% 
(vol/vol) Triton X-100, 10% (vol/vol) normal goat serum) at room temperature for 1 h.  
Labeling of vimentin and fluorophore cleavage under different conditions  
Fixed and blocked HeLa CCL-2 cells were incubated with 5 µg/mL chicken anti-vimentin 
(Abcam) at room temperature for 1 h, and then with 10 µg/mL N3-Cy5 conjugated goat 
anti-chicken IgG at room temperature for 1 h. Stained cells were imaged in GLOX solution 
(0.37 mg/mL glucose oxidase, 1% catalase, 0.4% glucose and 10mM Tris HCl in 2× saline-
sodium citrate buffer (300 mM sodium chloride, 30 mM trisodium citrate, pH = 7.0)). 
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Subsequently, cells were incubated with 1, 10, 100 or 1000 mM TCEP (pH = 9.5) at 37 °C 
for 30 minutes (Figure 2.5.6); or cells were incubated with 100 mM TCEP (pH = 7.5, 8.5, 
9.5 or 10.5) at 37 °C for 30 minutes (Figure 2.5.7); or cells were incubated with 100 mM 
TCEP (pH = 9.5) at 37 °C for 5, 15, 30 or 60 minutes (Figure 2.5.8). After fluorophore 
cleavage, cells were imaged again in GLOX solution. 
Labeling of Ki67 and fluorophore cleavage  
Fixed and blocked HeLa CCL-2 cells were incubated with 5 µg/mL rabbit anti-Ki67 (Fisher 
Scientific) at room temperature for 1 h, and then with 10 µg/mL N3-Fluorescein (Figure 
2.5.5A), N3-Cy5 (Figure 2.5.5G), conventional Fluorescein (Figure 2.5.9A) or 
conventional Cy5 (Figure 2.5.9G) conjugated goat anti-rabbit IgG at room temperature for 
1 h. Stained cells were imaged in GLOX solution. Subsequently, cells were incubated with 
100 mM TCEP at 37 °C for 30 minutes, and then imaged again in GLOX solution. 
Labeling of α-tubulin and fluorophore cleavage 	
Fixed and blocked HeLa CCL-2 cells were incubated with (Figure 2.5.5J) or without 
(Figure 2.5.5K) 100 mM TCEP at 37 °C for 24 hours. After incubation with 5 µg/mL rat 
anti-α-tubulin (Novus) at room temperature for 1 h, cells were incubated with 10 µg/mL 
N3-TAMRA (Figure 2.5.5D) or conventional TAMRA (Figure 2.5.9D) conjugated goat 
anti-rat IgG at room temperature for 1 h. Stained cells were imaged in 2× saline-sodium 
citrate buffer. Subsequently, cells were incubated with 100 mM TCEP at 37°C for 30 
minutes, and then imaged again.  
2.6.6 Multiplexed protein analysis with CFA  
Fixed and blocked HeLa CCL-2 cells were incubated with 5 µg/mL N3-TAMRA 
conjugated primary antibodies at room temperature for 1 h. After imaged in 2× saline- 
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sodium citrate buffer, stained cells were incubated with 100 mM TCEP (pH = 9.5) at 37 
°C for 30 minutes, followed by the next immunofluorescence cycle. Rabbit anti-p-4E-BP1 
(Cell Signaling), mouse anti-Pan Cytokeratin (Sigma), rabbit anti-p-Akt (T308) (Cell 
Signaling), rabbit anti-p-Akt (S473) (Cell Signaling), rabbit anti-p-p44/42 MAPK (Cell 
Signaling), rabbit anti-EGF receptor (Cell Signaling), rabbit anti-c-erbB-2 (Fisher 
Scientific), rabbit anti-p53 (Cell Signaling), rabbit anti-Ki67 (Fisher Scientific), rabbit anti-
Ezh2 (Cell Signaling), chicken anti-Vimentin (Jackson Laboratory) and rabbit anti- 
Histone H4 (Abcam) were used sequentially as primary antibodies. To stain Ki67 in two 
consecutive immunofluorescence cycles, fixed and blocked HeLa CCL-2 cells were 
incubated with 5 µg/mL N3-TAMRA conjugated rabbit anti-Ki67 at room temperature for 
1 h. After imaged in 2× saline-sodium citrate buffer, stained cells were incubated with 100 
mM TCEP (pH = 9.5) at 37 °C for 30 minutes. Subsequently, the cells were incubated with 
5 µg/mL N3-TAMRA conjugated rabbit anti-Ki67 at room temperature for 1 h, and imaged 
in 2× saline-sodium citrate buffer. For control experiments, fixed and blocked HeLa CCL-
2 cells were incubated with 5 µg/mL TAMRA labeled primary antibodies at room 
temperature for 1 h. 
2.6.7 Imaging and data analysis  
Stained cells were imaged under a Nikon Ti-E epifluorescence microscope equipped with 
40× objective. Images were captured using a CoolSNAP HQ2 camera and analyzed with 
NIS-Elements Imaging software. Chroma filter 49011 was used for Fluorescein and Alexa 
488. Chroma filters 49004 and 49009 were used for TAMRA and Cy5, respectively. 
Images were aligned and overlaid using ImageJ. Protein expression heterogeneity and 
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correlation were analyzed using excel (Microsoft). The hierarchical clustering was 
performed with Cluster 3.0 (http://bonsai.hgc.jp/~mdehoon/software/cluster/).  
2.6.8 Fluorescence Microscope 
In a typical epifluorescent microscope set up, illuminated and emitted light travel through 
the same objective lens (Figure 2.4.15). A defined band of wavelength is generated by 
passing brightfield light from an arc-discharge lamp or other sources through a selective 
excitation filter. A dichroic mirror is used to reflect the excitation light (shorter 
wavelength) onto the specimen. The resulting emission light (longer wavelength) gathered 
by the objective passes through the dichroic mirror and is subsequently filtered by emission 
filter, which blocks unwanted excitation wavelength. Charged-coupled device (CCD) 
detector recognizes the emitted light as a photon signal and stores the image as a localized 
electrical charge. The electrical charge for each pixel is read out rapidly by the detector as 
an intensity profile of the picture; then it can be reconstructed and displayed on the 
computer screen. 
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CHAPTER 3 
HIGHLY MULTIPLEXED SINGLE-CELL IN SITU RNA AND DNA ANALYSIS 
WITH BIOORTHOGONAL CLEAVABLE FLUORESCENT OLIGONUCLEOTIDES 
3.1 Abstract 
The ability to profile transcripts and genomic loci comprehensively in single cells in situ 
is essential to advance our understanding of normal physiology and disease pathogenesis. 
Here we report a highly multiplexed single-cell in situ RNA and DNA analysis approach 
using bioorthogonal cleavable fluorescent oligonucleotides. In this approach, 
oligonucleotides tethered to fluorophores through an azide-based cleavable linker are used 
to detect their nucleic acids targets by in situ hybridization. After fluorescence imaging, 
the fluorophores in the whole specimen are efficiently cleaved in 30 minutes without loss 
of RNA or DNA integrity. Through reiterative cycles of hybridization, imaging, and 
cleavage, this method has the potential to quantify hundreds to thousands of different RNA 
species or genomic loci in single cells in situ at the single-molecule sensitivity. Applying 
this approach, we demonstrate that different nucleic acids can be detected in each 
hybridization cycle by multi-color staining, and at least ten continuous hybridization cycles 
can be carried out in the same specimen. We also show that the integrated single- cell in 
situ analysis of DNA, RNA and protein can be achieved using cleavable fluorescent 
oligonucleotides combined with cleavable fluorescent antibodies. This highly multiplexed 
imaging platform will have wide applications in systems biology and biomedical research.  
3.2 Introduction 
Comprehensive analyses of the copy number and spatial organization of transcripts and 
genomic loci in single cells promise to transform our understanding of many heterogeneous 
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biological systems, such as brain tissues, solid tumors and developing embryos1. 
Microarray technologies2 and high-throughput sequencing3-6 have been widely used for 
transcriptome- or genome-wide nucleic acids analysis. Nonetheless, as these approaches 
are carried out with extracted DNA or RNA, they mask the spatial complexity of nucleic 
acids in a heterogeneous population. Fluorescent hybridization probes7-12 have emerged as 
a powerful tool to quantify transcripts and genomic loci in their natural spatial contexts in 
single cells. However, only a handful of different nucleic acids species in a biological 
sample can be detected by these fluorescence imaging-based approaches.  
To enable multiplexed single-cell in situ nucleic acids analysis, a number of 
methods have been explored. For example, in situ sequencing13, 14 has been developed to 
enable single-cell transcriptome analysis. However, it suffers from low detection efficiency 
and may miss transcripts with low copy numbers. Combinatorial labeling15-17 offers single-
molecule detection sensitivity, but it has limited multiplexing capacities. Recently, 
sequential hybridization18-20, multiplexed error-robust fluorescence in situ hybridization 
(MER-FISH)21-23 and reiterative hybridization24-26 have been developed. To allow multiple 
analysis cycles in the same specimen, these methods apply different approaches to remove 
the fluorescence signals. Such approaches include probe degradation by DNase, 
photobleaching, disulfide-based chemical cleavage, and probe stripping by formamide. 
Nevertheless, probe degradation by DNase has limited efficiency and is time-consuming. 
Photobleaching removes fluorescence signals in individual imaging areas sequentially, and 
thus has long assay time and low sample throughput. The endogenous thiol groups and the 
thiol groups generated by cleavage can react with the disulfide containing probes applied 
in the following cycles, generating high background and false positive signals. Probe 
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stripping by formamide removes all the probes, including the large oligonucleotides library 
hybridized to their RNA and DNA targets. As a result, this expensive oligonucleotides 
library has to be re-hybridized in every analysis cycle, which makes this approach less cost- 
and time-effective. Additionally, removal of the stripped oligonucleotides probes by 
diffusion in thick tissue samples can be inefficient and time-consuming, limiting its 
applications for intact tissue analysis. 
Here, we report a highly multiplexed single-cell in situ RNA and DNA analysis 
approach using bioorthogonal cleavable fluorescent oligonucleotides (BoCFO). In this 
method, oligonucleotides (ON) conjugated to fluorophores through an azide- based 
chemically cleavable linker are applied to detect their nucleic acids targets by in situ 
hybridization. Upon continuous cycles of target hybridization, fluorescence imaging, and 
fluorophore cleavage, this approach has the potential to quantify hundreds to thousands of 
different RNA species or genomic loci in individual cells at the optical resolution. To 
demonstrate the feasibility of this approach, we designed and synthesized BoCFO by 
coupling oligonucleotides with different cleavable fluorophores. We show that the 
fluorophores conjugated to oligonucleotides can be efficiently cleaved within the cellular 
environment in 30 minutes at 37°C without loss of RNA or DNA integrity. We also 
demonstrate that different nucleic acids species can be detected in each hybridization cycle 
by multicolor staining, and at least ten continuous hybridization cycles can be carried out 
in the same set of cells. Additionally, we show that integrated single-cell in situ analysis of 
DNA, RNA and protein can be achieved by using cleavable fluorescent oligonucleotides 
together with cleavable fluorescent antibodies. Applying this approach, we studied RNA 
expression heterogeneity in a population of genetically identical cells, and performed the 
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expression correlation analysis between different RNA species and also between RNA and 
protein.  
3.3 Results and discussion 
As shown in Figure 3.4.1A and B, each hybridization cycle of this BoCFO-based RNA and 
DNA profiling technology consists of three steps. First, different RNA species or genomic 
loci are stained by BoCFO. This can be achieved using two alternative approaches. In the 
direct staining approach (Figure 3.4.1A), a set of BoCFO with varied sequences and the 
same fluorophore is hybridized to the different regions of each nucleic acids target. In the 
indirect staining approach (Figure 3.4.1B), individual nucleic acids target is first hybridized 
by a set of non-labeled pre-decoding oligonucleotides with varied target binding sequences. 
These oligonucleotides also have one or multiple decoding oligonucleotides binding 
sequences, which can recruit BoCFO in subsequent hybridization. Each of these two 
complementary approaches has unique advantages. The direct staining method has 
minimized probe cross-hybridization; while the indirect staining approach has enhanced 
signal to background ratio and reduced cost. In the second step, fluorescence images are 
acquired in each fluorescence channel. Under a fluorescence microscope, each RNA 
molecule or genomic locus is visualized as a single spot. Finally, all the different 
fluorophores in the whole specimen are simultaneously removed by chemical cleavage of 
the linker. This signal removal step enables the initiation of the next hybridization cycle. 
Through reiterative cycles of target hybridization, fluorescence imaging and fluorophore 
cleavage, highly multiplexed RNA or DNA profiling can be achieved in single cells in situ. 
For example, by staining different nucleic acids in sequential hybridization cycles, an 
overall M x N nucleic acids can be quantified in individual cells in situ, where M is the 
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number of varied fluorophores used in each analysis cycle, and N is the number of 
hybridization cycles. When the same set of nucleic acids are stained in sequential 
hybridization cycles (Figure 3.4.2), each nucleic acid is identified by a fluorescence 
sequence barcode. In this case, with M fluorophores applied in each cycle and N sequential 
cycles, a total of MN nucleic acids can be profiled in single cells in situ. 
 To demonstrate the feasibility of this BoCFO-based RNA and DNA profiling 
approach, we designed and synthesized nine libraries of direct staining probes and three 
libraries of indirect staining probes. The direct staining probes target mRNA topo- 
isomerase I (TOP1), V-akt murine thymoma viral oncogene homolog 1 (AKT1), transferrin 
receptor (TFRC), breast cancer 1 (BRCA1), breast cancer 2 (BRCA2), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), polymerase II polypeptide A (POLR2A), actin beta 
(ACTB) and PR domain containing 4 (PRDM4). Each library of the direct staining probes 
is composed of about forty 20 mer BoCFO. The indirect staining probes target mRNA 
GAPDH and marker of proliferation Ki-67 (MKI67), along with a 5 kb genomic locus at 
4p16.1. Each library of the indirect mRNA and DNA staining probes is composed of ~ 40 
and 100 predecoding oligonucleotides, respectively. These pre- decoding oligonucleotides 
include one target binding site, one or multiple decoding oligonucleotides binding sites, 
and poly-T linkers inserted between the binding sites. Each library of the pre-decoding 
oligonucleotides can recruit a corresponding decoding oligonucleotide, which is 
conjugated with cleavable fluorophores and function as BoCFO.  
 To prepare BoCFO, we tethered fluorophores to oligonucleotides through an azide-
based cleavable linker in three steps27. First, Quasar 570 (Scheme 3.5.1), and Cy5 N-
hydroxysuccinimide (NHS) ester (Scheme 3.5.2) were coupled to the cleavable linker. 
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Subsequently, the coupling products were converted to their corresponding NHS esters. 
Finally, the cleavable fluorophore NHS esters were coupled with the amino groups on 
oligonucleotides to afford ON-N3-Quasar 570 and ON-N3-Cy5 (Figure 3.4.1). The 
synthesized BoCFO were purified by high-performance liquid chromatography (HPLC) 
(Figure 3.4.3) to remove excess fluorophores and unlabeled oligonucleotides. Unlike the 
disulfide-based probes, these BoCFO probes don't cross-react with cellular biomolecules, 
as the azide group is inert toward endogenous biological functionalities28, 29. Additionally, 
after cleavage by Staudinger reaction, the hydroxyl group left on the oligonucleotides 
(Figure 3.4.4) will not react with the probes applied in subsequent cycles. Therefore, the 
false positive signals generated by cross-reactions between different probes are also 
avoided.  
 One critical requirement for the success of this BoCFO-based RNA and DNA 
profiling technology is that fluorophores need to be cleaved very efficiently at the end of 
each hybridization cycle within the cellular environment. In this way, the minimum 
fluorescence signal left over generated in previous cycles will not result in false positive 
signals in the subsequent cycles. To assess the fluorophore cleavage efficiency, we stained 
mRNA GAPDH (Figure 3.4.5A) with ON-N3-Quasar 570 using the direct staining 
approach, mRNA MKI67 (Figure 3.4.5D) and genomic locus 4p16.1 (Figure 3.4.5G) with 
ON-N3-Cy5 using the indirect staining approach. To evaluate the signal removal efficiency 
at different cleavage times, we incubated the stained cells with tris(2- 
carboxyethyl)phosphine (TCEP) for 15, 30 and 60 minutes at 37 °C (Figure 3.4.6). Among 
these conditions, 30 minutes is the minimum time required to achieve the maximum 
cleavage efficiency. Thus, the cleavage time of 30 minutes was applied to remove the 
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fluorescence signals from labeled mRNA GAPDH, MKI67 and genomic locus 4p16.1. 
After cleavage, the fluorescence signals were removed almost completely (Figure 3.4.5B, 
E and H), and almost all the original FISH spots become undetectable (Figure 3.4.5C, F 
and I). We also performed control experiments by staining mRNA GAPDH and genomic 
locus 4p16.1 with conventional non-cleavable RNA and DNA FISH probes (Figure 3.4.7). 
After the TCEP treatment, the fluorescence intensities of the Quasar 570 and Cy5 stained 
GAPDH and Cy5 stained 4p16.1 remained largely unchanged. These results suggest that 
the fluorescence signals generated by hybridization of BoCFO can be efficiently erased 
using TCEP by cleavage of the fluorophores attached to oligonucleotides.  
Another requirement for the success of this BoCFO-based approach is that the 
TCEP treatment should not lead to loss of RNA or DNA integrity. It has been documented 
that the integrity of genome30 and transcriptome22, 23 is maintained following the repeated 
TCEP treatment. To further assess the effects of the TCEP treatment on RNA targets, we 
incubated the fixed cells with TCEP for 24 hours, and then applied the direct staining 
approach to label mRNA ACTB with ON-N3-Quasar 570 (Figure 3.4.8A) and the indirect 
staining approach to label mRNA MKI67 with ON-N3-Cy5 (Figure 3.4.8C). We also 
stained these two mRNA using the conventional RNA FISH approach without the 
pretreatment of TCEP (Figure 3.4.8B and D). The expression patterns (Figure 3.4.8A–D) 
and copy numbers (Figure 3.4.8G) obtained by these two methods closely resemble each 
other. To assess the effects of the TCEP treatment on DNA integrity, we incubated the 
fixed cells with TCEP for 24 hours, and then applied the indirect staining approach to label 
genomic locus 4p16.1 with ON-N3-Cy5. The obtained spatial distribution (Figure 3.4.8E) 
and copy number (Figure 3.4.8H) are similar to those generated using the conventional 
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DNA FISH approach without the pretreatment of TCEP (Figure 3.4.8F and H). These 
results indicate that the RNA and DNA integrity is maintained after the TCEP treatment, 
which allows the nucleic acids in the same specimen to be accurately profiled in subsequent 
cycles. 
 To quantify hundreds of RNA species simultaneously in single cells by sequential 
staining19, 21-23, an expensive oligonucleotide library containing thousands of pre-decoding 
probes have to be first hybridized to their RNA targets. Additionally, the hybridization of 
this pre-decoding oligonucleotide library (overnight to 36 hours) takes much longer than 
the hybridization of the subsequent decoding probes (15 to 30 minutes). Therefore, to 
minimize the assay cost and time, it is preferred to keep the pre-decoding probes hybridized 
to their targets throughout the assay, rather than to remove them by DNase or formamide 
and re-hybridize them later in every analysis cycle. To demonstrate that the predecoding 
probes remain in the same place after the TCEP treatment, we stained mRNA GAPDH in 
three continuous hybridization cycles (Figure 3.4.9). In each cycle, the decoding probe 
hybridizes to the probe used in the previous cycle, and also introduces binding sites for the 
probe of the following cycle. With this approach, 99% of the spots co-localized in the first 
two cycles reappear in the third cycle (n = 1036 spots). In comparison, only 78% of the 
spots reoccur in the third cycle when DNase is applied to remove the all the probes in every 
analysis cycle18. These results confirm that the TCEP treatment does not damage the 
nucleic acids integrity, which allows the pre-decoding probes to remain hybridized to their 
targets throughout the analysis cycles. In this way, the assay cost and time are reduced and 
the analysis accuracy is enhanced. 
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 To evaluate the effectiveness of our approach to quantify different nucleic acids in 
one hybridization cycle, we used the indirect staining method to simultaneously label 
mRNA MKI67 and GAPDH with ON-N3-Quasar 570 and ON-N3-Cy5, respectively. The 
obtained expression patterns (Figure 3.4.10A) and copy numbers (Figure 3.4.10B) closely 
resemble those generated by the conventional RNA FISH approach (Figure 3.4.8D, 3.4.7D 
and 3.4.10B). These results suggest that our BoCFO-based approach enables the 
quantitative analysis of different nucleic acids in each hybridization cycle by multi-color 
staining. 
 To demonstrate the multi-cycle potential of our approach, we quantified 10 RNA 
species in the same set of cells with one transcript stained in each cycle using only ON-N3-
Cy5. Through reiterative cycles of target hybridization, fluorescence imaging, and 
fluorophore cleavage, mRNA TOP1, AKT1, TFRC, BRCA1, MKI67, BRCA2, GAPDH, 
POLR2A, ACTB and PRDM4 were unambiguously detected with the combined direct and 
indirect staining approaches (Figure 3.4.11A). We also performed control experiments to 
stain these 10 RNA species in 10 different sets of cells using the conventional RNA FISH 
method (Figure 3.4.11B). The expression patterns obtained by these two approaches 
(Figure 3.4.11A and B) closely resemble each other. To evaluate the accuracy of our 
approach, we measured the average copy numbers of transcripts per cell generated by our 
approach and conventional RNA FISH. For all the 10 transcripts with copy numbers per 
cell ranging from 10 to 1000, the results obtained by the two methods (Figure 3.4.12A), 
together with those reported previously using RNA-Seq31, are consistent with each other. 
Comparison of the results obtained using our method and conventional RNA FISH yields 
an R2 value of 0.99 with a slope of 0.99 (Figure 3.4.13). These results confirm that the 
	 76	
nucleic acids integrity is maintained following the repeated TCEP treatment. We also 
compared the signal-to-noise ratios generated by our approach and conventional RNA 
FISH (Figure 3.4.12B). The results obtained by both methods are similar for all the measure 
transcripts. These results demonstrate that the BoCFO-based approach enables quantitative 
and comprehensive nucleic acids profiling in single cells in situ by multi-cycle staining.  
As demonstrated in many experiments, genetically identical cells can exhibit 
significant cell-to-cell variations in gene expression32-38. Our BoCFO-based single-cell 
nucleic acids profiling approach allows the investigation of such cell-to-cell expression 
heterogeneity. As shown in Figure 3.4.14A, the RNA copy numbers per cell are distributed 
in a wide range. This significant expression variation leads to the relatively large error bars 
in Figure 3.4.13. For all the 10 measured transcripts, the square of the expression standard 
deviation is much higher than the mean copy numbers. These results suggest that the 10 
measured transcripts are generated in bursts rather than at a constant rate39.  
To study expression correlation of different RNA species, bulk cell experiments 
usually require external stimuli to introduce gene expression variation. At the single-cell 
level, stochastic gene expression generates expression variation in individual cells 
naturally. This allows us to perform single-cell expression correlation analysis to study 
whether transcription of different genes is coordinated. Using this approach, we examined 
the pairwise expression covariation of the 10 measured transcripts, and calculated the 
corresponding correlation coefficient of each transcript pair (Figure 3.4.14B). These 
correlation coefficients range from 0.41 to 0.73, suggesting that the synthesis of these 
measured transcripts is heterogeneously coordinated. 
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Combined analysis of nucleic acids and proteins in the same specimen in situ is of 
increasing importance in disease diagnosis40 and studies of gene expression regulation41. 
Recently, our laboratory developed cleavable fluorescent antibodies for multiplexed 
single-cell in situ protein analysis42. We demonstrated that the fluorophores tethered to 
antibodies through a cleavable linker can be efficiently cleaved using TCEP without loss 
of protein antigenicity. We also documented that comprehensive in situ protein profiling 
can be achieved through continuous cycles of protein binding, fluorescence imaging and 
fluorophore cleavage.  
To test the hypothesis of applying BoCFO together with cleavable fluorescent 
antibodies (CFA) for integrated DNA, RNA and protein in situ profiling, we stained protein 
Ki67, mRNA MKI67 and genomic locus 4p16.1 in the same set of cells. Cells were first 
incubated with cleavable Cy5 conjugated antibodies to stain protein Ki67 (Figure 3.4.15A). 
Afer removing the fluorescence signals with TCEP, mRNA MKI67 (Figure 3.4.15B) and 
genomic locus 4p16.1 (Figure 3.4.15C) were sequentially stained with ON-N3-Cy5 using 
the indirect staining approach. The obtained spatial distributions (Figure 3.4.15A–C) and 
abundances (Figure 3.4.16A–C) closely resemble those (Figure 3.4.15D, 3.4.8D, F and 
3.4.16A–C) generated by conventional immunofluorescence and FISH methods. These 
results indicate our approach enables the direct visualization (Figure 3.4.17A) and 
quantitative analysis of DNA, RNA and protein molecules together in the same specimen.  
To study whether the copy numbers of transcripts can be used to predict the 
abundances of the corresponding proteins, we performed the single-cell RNA-protein 
expression correlation analysis. This analysis of mRNA MKI67 and protein Ki67 yields 
the correlation coefficient value of 0.54 (Figure 3.4.17B). These results are in line with the 
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weak correlations between mRNA and protein levels reported previously43, and suggest 
that post-transcriptional regulation plays an import role on protein synthesis. 
We have designed and synthesized BoCFO, and applied them for multiplexed 
single cell in situ nucleic acids profiling. Compared with the existing technologies, our 
approach has the following advantages. (i) In this method, nucleic acids targets are detected 
directly by in situ hybridization without target sequence amplification. Therefore, 
transcripts and genomic loci can be visualized at the single-molecule sensitivity. (ii) Our 
technology has high multiplexing capacity as it allows a large number of the same or 
different nucleic acids to be detected in different analysis cycles by sequential staining or 
reiterative hybridization, respectively. (iii) The TCEP treatment simultaneously cleaves all 
the different fluorophores in the whole specimen within 30 minutes. Thus, our method has 
high sample throughput, and permits a large number of cells to be analyzed in a short time. 
(iv) As BoCFO has high signal removal efficiency and avoids the cross-reactions with 
endogenous biomolecules and other probes, our approach has enhanced signal to noise 
ratio and analysis accuracy. (v) Rather than re-hybridizing the expensive target-binding 
oligonucleotide library in every analysis cycle, our technology only applies this time-
consuming hybridization in the first cycle. Therefore, our method is more time- and cost-
effective. (vi) As the small cleaved fluorophores diffuse out faster than the large stripped 
oligonucleotide probes, our technology facilitates the analysis of intact tissues. (vii) By 
cleaving the fluorophores while maintaining the integrity of almost all the biomolecules, 
our approach can be applied for the integrated single-cell in situ DNA, RNA and protein 
analysis. 
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The number of nucleic acids that can be quantified in single cells using this BoCFO-
based approach depends on two factors: the number of hybridization cycles and the number 
of fluorophores applied in each cycle. As we have shown, TCEP can efficiently remove 
the fluorophores within 30 minutes, while the integrity of RNA and DNA is preserved after 
the treatment with TCEP for at least 24 hours. This suggests that the cycling number can 
be further increased significantly. Additionally, classical fluorophores with four or five 
varied colors can be applied simultaneously to visualize different nucleic acids in one 
hybridization cycle. And multispectral fluorophores coupled with the hyperspectral 
imaging method44 will enable more fluorophores to be differentiated and applied in each 
hybridization cycle. Therefore, by combining reiterative hybridization and sequential 
staining to quantify nucleic acids with high and low copy numbers, respectively, we 
envision that this BoCFO-based approach has the potential to detect hundreds to thousands 
of nucleic acids species at the single molecule sensitivity in single cells in situ. 
Additionally, the BoCFO probes developed here integrated with cleavable fluorescent 
antibodies we reported previously enable the comprehensive and integrated DNA, RNA 
and protein profiling at the optical resolution in single cells. This highly multiplexed 
imaging platform will bring new insights into cell signaling network, gene expression 
regulation, molecular diagnosis and cellular targeted therapy. 
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3.4 Figures 
 
Figure 3.4.1 Highly multiplexed single cell in situ RNA and DNA analysis with BoCFO. 
Each hybridization cycle starts with target staining, which can be achieved with two 
alternative approaches. (A) In the direct staining approach, each nucleic acids target is 
hybridized with a set of BoCFO. (B) In the indirect staining approach, individual nucleic 
acids target is first hybridized by a set of non-labeled oligonucleotides, which are 
subsequently hybridized by BoCFO. For both approaches, after target hybridization, the 
fluorescence images are captured. Finally, all the different fluorophores on BoCFO are 
chemically cleaved simultaneously. Through cycles of target hybridization, fluorescence 
imaging and fluorophore cleavage, a large number of distinct transcripts or genomic loci 
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can be quantified at the single-molecule sensitivity in single cells in situ. (C) Structures of 
BoCFO, ON-N3-Quasar 570 and ON-N3-Cy5. 
 
 
 
 
 
 
 
Figure 3.4.2 Staining of the same targets in sequential hybridization cycles using BoCFO. 
In the direct staining approach (A), BoCFO are hybridized to the varied binding sites on 
the same targets in different analysis cycles. In the indirect staining approach, targets are 
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first hybridized to all the predecoding probes simultaneously. Subsequently, BoCFO are 
hybridized to the varied predecoding probes (B) or distinct binding sites (C) on the same 
predecoding probes in different analysis cycles. 
 
 
Figure 3.4.3 Sample HPLC chromatographs of purified (A) ON-N3-Quasar 570 and (B) 
ON-N3- Cy5.  
 
 
 
Figure 3.4.4 Mechanisms to cleave fluorophores from bioorthogonal cleavable 
fluorescent oligonucleotides by Staudinger reaction. 
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Figure 3.4.5 A) GAPDH transcripts are detected with ON-N3-Quasar 570 using the direct 
staining approach. (B) Quasar 570 is cleaved by TCEP. (C) Fluorescence intensity profiles 
corresponding to the yellow lines positions in (A) and (B). (D) MKI67 transcripts are 
detected with ON-N3-Cy5 using the indirect staining approach. (E) Cy5 is cleaved by 
TCEP. (F) Fluorescence intensity profiles corresponding to the yellow lines positions in 
(D) and (E). (G) Genomic locus 4p16.1 is stained with ON-N3-Cy5 using the indirect 
staining approach. (H) Cy5 is cleaved with TCEP. Cell nuclei are stained with DAPI (blue) 
in (G) and (H). (I) Fluorescence intensity profiles corresponding to the yellow lines 
positions in (G) and (H). Scale bars, 5 µm. 
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Figure 3.4.6 Signal removal efficiency at different cleavage times. (A) Cells with GAPDH 
transcripts stained with ON-N3-Quasar 570 are incubated with TCEP for 15, 30 or 60 
minutes. (B) Fractions of spots that are removed by fluorophore cleavage at different 
reaction times (n = 30 cells).  
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Figure 3.4.7 (A) GAPDH transcripts are detected with conventional Quasar 570 labeled 
RNA FISH probes and (B) subsequently incubated with TCEP. (C) Fluorescence intensity 
profiles corresponding to the yellow lines positions in (A) and (B). (D) GAPDH transcripts 
are detected with conventional Cy5 labeled RNA FISH probes and (E) subsequently 
incubated with TCEP. (F) Fluorescence intensity profiles corresponding to the yellow lines 
positions in (D) and (E). (G) Genomic locus 4p16.1 is detected with conventional Cy5 
labeled DNA FISH probes and (H) subsequently incubated with TCEP. Cell nuclei are 
stained with DAPI (blue) in (G) and (H). (I) Fluorescence intensity profiles corresponding 
to the yellow lines positions in (G) and (H). Scale bars, 5 µm. 
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Figure 3.4.8 (A) After incubation with TCEP for 24 hours, ACTB transcripts are detected 
with ON-N3-Quasar 570 using the direct staining approach. (B) Without incubation with 
TCEP, ACTB transcripts are detected by conventional RNA FISH. (C) After incubation 
with TCEP for 24 hours, MKI67 transcripts are detected with ON-N3-Cy5 using the 
indirect staining approach. (D) Without TCEP incubation, MKI67 transcripts are detected 
by conventional RNA FISH. (E) After incubation with TCEP for 24 hours, genomic locus 
4p16.1 is detected with ON-N3-Cy5 using the indirect staining approach. (F) Without 
incubation with TCEP, genomic locus 4p16.1 is detected by conventional DNA FISH. Cell 
nuclei are stained with DAPI (blue) in (E) and (F). (G) The mean copy number of ACTB 
and MKI67 transcripts per cell obtained with and without the TCEP treatment before 
hybridization (P > 0.3; error bars, s.d.; n = 30 cells). The y axe in (G) is on a logarithmic 
scale. (H) Copy numbers of genomic locus 4p16.1 per cell (n = 30 cells) obtained with and 
without the TCEP treatment before hybridization. Scale bars, 5 µm. 
 
 
	 87	
Figure 3.4.9 (A) GAPDH transcripts are detected with ON-N3-Quasar 570 using the 
indirect staining approach. (B) Quasar 570 is cleaved by TCEP. (C) In the second cycle, 
GAPDH transcripts in the same cell are stained using ON-N3-Cy5. (D) Cy5 is cleaved by 
TCEP. (E) In the third cycle, GAPDH transcripts in the same cell are stained using ON-
N3-Quasar 570. (F) Quasar 570 is cleaved by TCEP. (G) Digital overlay of (A) and (C). 
(H) Digital overlay of (C) and (E). (I) Fluorescence intensity profiles corresponding to the 
yellow lines positions in (A) and (B). (J) Fluorescence intensity profiles corresponding to 
the yellow lines positions in (C) and (D). (K) Fluorescence intensity profiles corresponding 
to the yellow lines positions in (E) and (F). Scale bars, 5 µm. 
 
 
 
Figure 3.4.10 A) MKI67 and GAPDH transcripts are detected in the same cell using the 
indirect staining approach with ON-N3-Quasar 570 (green) and ON-N3-Cy5 (red), 
respectively. (B) The mean copy numbers of MKI67 and GAPDH transcripts per cell 
measured by RNA FISH with BoCFO and conventional RNA FISH (P > 0.2; error bars, 
s.d.; n = 30 cells). The y axe in (B) is on a logarithmic scale. Scale bars, 5 µm. 
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Figure 3.4.11 (A) Ten different transcripts are detected with the corresponding ON-N3-
Cy5 in the same set of cells. (B) Ten different transcripts are detected in different cells by 
conventional RNA FISH. Scale bars, 5 µm. 
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Figure 3.4.12 (A) Mean copy number per cell of the ten transcripts measured by RNA 
FISH with BoCFO and conventional RNA FISH (P > 0.2; n = 30 cells). The axes in (A) 
are on a logarithmic scale. (B) Mean signal-to-noise ratios of the ten transcripts measured 
by RNA FISH with BoCFO and conventional RNA FISH (P > 0.2; n = 30 spots). Error 
bars, s.d.  
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Figure 3.4.13 Comparison of the results obtained by RNA FISH with BoCFO and 
conventional RNA FISH yields R2 = 0.99 with a slope of 0.99. The axes are on a 
logarithmic scale. Error bars, s.d. 
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Figure 3.4.14 Gene expression heterogeneity and correlation. (A) Histograms of the copy 
number distribution of the 10 measured mRNA species (n = 30 cells). (B) Correlation of 
the expression levels of the 10 measured transcripts (n = 30 cells). The lower triangle 
displays the expression correlation coefficient of each gene pair. And the upper triangle 
shows the color corresponding to the correlation coefficient. 
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Figure 3.4.15 (A) Ki-67 protein is detected with Ab-N3-Cy5 (yellow). (B) mRNA MKI67 
is detected with ON-N3-Cy5 (green). (C) Genomic locus 4p16.1 is detected with ON-N3-
Cy5 (red). (D) Ki- 67 protein is detected with conventional Cy5 conjugated antibodies 
(yellow). Cell nuclei are stained with DAPI (blue). Scale bars, 5 µm. 
 
 
Figure 3.4.16 (A) Mean expression level per cell of protein Ki-67 measured by 
immunofluorescence (IF) with CFA and conventional IF (P > 0.2; n = 30 cells). (B) Mean 
copy number per cell of mRNA MKI67 measured by RNA FISH with BoCFO and 
conventional RNA FISH (P > 0.3; n = 30 cells). (C) Mean copy number per cell (n = 30 
cells) of genomic locus 4p16.1 measured by DNA FISH with BoCFO and conventional 
DNA FISH. Error bars, s.d.  
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Figure 3.4.17 (A) Ki-67 protein (yellow), mRNA MKI67 (green) and genomic locus 
4p16.1 (red) are sequentially detected with Ab-N3-Cy5, ON-N3-Cy5 and ON-N3-Cy5, 
respectively. Cell nuclei are stained with DAPI (blue). Scale bars, 5 µm. (B) Raw 
expression correlation data of mRNA MKI67 and protein Ki-67, each spot corresponds to 
one cell with transcript copy numbers in the xaxis and protein expression levels in 
the y axis. 
 
3.5 Schemes 
 
 
 
Scheme 3.5.1 Synthesis of ON-N3-Quasar 570. Reagents and conditions: (i) DIPEA, DMF, 
rt, 2 h. (ii) N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, N-
hydroxysucci- nimide, DMF, rt, 5 h. (iii) 3’ Amino-modified oligonucleotides, 1 M sodium 
tetraborate (pH 8.5), rt, 6 h.  
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Scheme 3.5.2 Synthesis of ON-N3-Cy5. Reagents and conditions: (i) DIPEA, DMF, rt, 2 
h. (ii) N- (3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, N-
hydroxysuccinimide, DMF, rt, 5 h. (iii) 3’ Amino-modified oligonucleotides, 1 M sodium 
tetraborate (pH 8.5), rt, 6 h.  
 
3.6 Methods 
3.6.1 General information 
Chemicals and solvents were purchased from Sigma-Aldrich or TCI America and were 
used directly without further purifications, unless otherwise noted. Bioreagents were 
purchased from Invitrogen or Ambion, unless otherwise indicated. 1H NMR was performed 
on Varian Innova 500 MHz NMR spectrometers. Chemical shifts are reported in parts per 
million (ppm) downfield from tetramethylsilane (TMS). Data are reported as follows: 
chemical shift, multiplicity: singlet (s), doublet (d), triplet (t), multiplet (m), coupling 
constants J in Hz, and integration. High resolution mass spectrometry (HRMS) was 
performed by Arizona State University mass spectrometry facility.  
3.6.2 Design and synthesis of BoCFO-based probes  
	 95	
The 3’ amino-modified direct staining probes were purchased from Biosearch 
Technologies as custom-made probes. The sequences of the indirect staining probes (Table 
S1) were designed using the RNA8 and DNA9 FISH probe design software. The unlabeled 
predecoding and 3’ amino-modified decoding indirect staining probes were synthesized by 
Integrated DNA Technologies (IDT). The synthesis and characterization of cleavable 
fluorescent oligonucleotides (ON-N3-Quasar 570 and ON-N3-Cy5) are described below.  
Synthesis of ON-N3-Quasar 570  
N3-Quasar 570 (2): Compound 1 (10 mg, 27.24 µmol) prepared according to the 
literature27 was dissolved in anhydrous DMF (300 µL). N,N-Diisopropylethylamine 
(DIPEA) (4.6 µL, 27.24 µmol) was added to the above solution and stirred at room 
temperature for 5 min. Subsequently, Quasar 570 N-hydroxysuccinimide (NHS) ester 
(BioSearch Technologies) (9.5 mg, 13.62 µmol) in 40 µL of anhydrous DMF was added to 
the reaction mixture. The reaction mixture was stirred at room temperature for 2 h. After 
completion of the reaction, DMF was removed completely under vacuum. The crude 
product was purified by a preparative silica gel TLC plate (25 X 25 cm; silica gel 60; 
CH3OH:CH2Cl2 = 1:6; Rf = 0.2) to afford compound 2 (8.2 mg, 51%) as a pink solid. 1H 
NMR (500 MHz, CD3OD) δ 8.52 (t, J = 13.4 Hz, 1H), 7.53 (t, J = 6.4 Hz, 2H), 7.47- 7.39 
(m, 4H), 7.36-7.26 (m, 5H), 7.08 (d, J = 8.2 Hz, 1H), 6.50 (d, J = 13.5 Hz, 1H), 6.42 (d, J 
= 13.4 Hz, 1H), 4.99 (t, J = 5.0 Hz, 1H), 4.23-4.15 (m, 3H), 4.11-4.05 (m, 1H), 4.03-3.98 
(m, 2H), 3.97-3.92 (m, 1H), 3.90 (s, 2H), 3.86-3.80 (m, 1H), 3.72-3.63 (m, 2H), 3.50 (t, J 
= 5.8 Hz, 2H), 3.41 (t, J = 5.8 Hz, 2H), 2.23 (t, J = 7.2 Hz, 2H), 1.81-1.73 (m, 13H), 1.71-
1.63 (m, 3H), 1.46- 1.36 (m, 5H); HRMS (ESI+, m/z) calcd for C46H58N7O7 [(M)+]: 
820.4398, found: 820.4460.  
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N3-Quasar 570 NHS ester (3): To a stirred solution of compound 2 (2.0 mg, 2.39 µmol) 
in anhydrous DMF (300 µL), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (2.3 mg, 11.95 µmol) and N-hydroxysuccinimide (1.4 mg, 11.95 µmol) were 
added. The reaction mixture was stirred at room temperature for 5 h. After completion of 
the reaction, DMF was removed completely under vacuum. After adding 30 mL of 
dichloromethane, the organic layer was extracted with 2.5% NaHSO4 for two times. Then 
the organic layer was further washed with brine, dried over anhydrous MgSO4 and 
evaporated under vacuum to afford compound 3 as a pink solid. The crude product was 
used directly for oligonucleotide labeling.  
ON-N3-Quasar 570 (4): 3’ Amino-modified direct staining probes belonging to one library 
(Biosearch Technologies) (each at a scale of 25 pmol), or 3’ amino-modified secondary 
indirect staining probes (1 nmol) were dissolved in 1 µL of nuclease-free 1× phosphate 
buffered saline (PBS) buffer (pH 7.4). To this solution, 1 µL of nuclease-free water, 3 µL 
of sodium tetraborate (1 M, pH 8.5) and 5 µL of compound 3 (20 mM) dissolved in 
anhydrous DMF were added. The reaction mixture was then incubated at room temperature 
for 6 h. Subsequently, the N3-Quasar 570 coupled oligonucleotides were purified by 
nucleotide removal kit (Qiagen) and then further purified via an HPLC equipped with a 
C18 column (Agilent) and a dual wavelength detector set to detect DNA absorption (260 
nm) as well as the absorption of the coupled Quasar 570 (550 nm). For the gradient, triethyl 
ammonium bicarbonate buffer (0.1 M, pH 8.0) (Buffer A) and acetonitrile (pH 6.5) (Buffer 
B) were used, ranging from 7% to 30% Buffer B over the course of 5 min, then 30% to 
46% Buffer B over the course of 25 min, after that at 70% Buffer B for 10 min followed 
by 7% Buffer B for another 10 min, all at a flow rate of 1 mL/min. The collected fraction 
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was dried in a lyophilizer and stored as a stock probe solution at 4°C in 120 µL of nuclease 
free 1× PBS buffer (pH 7.4).  
N3-Cy5 (5): Compound 1 (10 mg, 27.24 µmol) prepared according to the literature27 was 
dissolved in anhydrous DMF (300 µL). N,N-Diisopropylethylamine (DIPEA) (4.6 µL, 
27.24 µmol) was added to the above solution and stirred at room temperature for 5 min. 
Subsequently, Cy5 N-hydroxysuccinimide (NHS) ester (AAT Bioquest) (8.4 mg, 13.62 
µmol) in 40 µL of anhydrous DMF was added to the reaction mixture. The reaction mixture 
was stirred at room temperature for 2 h. After completion of the reaction, DMF was 
removed completely under vacuum. The crude product was purified by a preparative silica 
gel TLC plate (25 X 25 cm; silica gel 60; CH3OH:CH2Cl2 = 1:5; Rf = 0.3) to afford 
compound 5 (6.7 mg, 49%) as a blue solid. 1H NMR (500 MHz, CD3OD) δ 8.23 (t, J = 
13.0 Hz, 2H), 7.50-7.38 (m, 6H), 7.34 (t, J = 7.9 Hz, 1H), 7.31-7.22 (m, 4H), 7.09 (d, J = 
7.8 Hz, 1H), 6.62 (t, J = 12.4 Hz, 1H), 6.28-6.21 (m, 2H), 5.00 (t, J = 5.0 Hz, 1H), 4.22-
4.18 (m, 1H), 4.11-4.07 (m, 1H), 4.01-3.94 (m, 3H), 3.92 (s, 2H), 3.88-3.82 (m, 1H), 3.72-
3.68 (m, 2H), 3.60 (s, 3H), 3.51 (t, J = 5.9 Hz, 2H), 3.42 (t, J = 5.8 Hz, 2H), 2.23 (t, J = 7.1 
Hz, 2H), 1.79-1.64 (m, 15H), 1.45-1.38 (m, 3H); HRMS (ESI+, m/z) calcd for C47H58N7O7 
[(M)+]: 832.4398, found: 832.4366.  
N3-Cy5 NHS ester (6): To a stirred solution of compound 5 (2.0 mg, 2.39 µmol) in 
anhydrous DMF (300 µL), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (2.3 mg, 11.95 µmol) and N-hydroxysuccinimide (1.4 mg, 11.95 µmol) were 
added. The reaction mixture was stirred at room temperature for 5 h. After completion of 
the reaction, DMF was removed completely under vacuum. After adding 30 mL of 
dichloromethane, the organic layer was extracted with 2.5% NaHSO4 for two times. Then 
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the organic layer was further washed with brine, dried over anhydrous MgSO4 and 
evaporated under vacuum to afford compound 6 as a pink solid. The crude product was 
used directly for oligonucleotide labeling. The crude product was used directly for 
oligonucleotides labeling.  
ON-N3-Cy5 (7): The preparation procedure was similar to the synthesis of ON-N3-Quasar 
570.  
3.6.3 Synthesis of conventional fluorescent oligonucleotides  
Conventional Quasar 570 and Cy5 labeled oligonucleotides were prepared according to the 
literature25. Briefly, 3’ amino-modified direct staining probes belonging to one library 
(Biosearch Technologies) (each at a scale of 25 pmol), or 3’ amino-modified decoding 
indirect staining probes (1 nmol) were dissolved in 1 µL of nuclease-free 1× phosphate 
buffered saline (PBS) buffer (pH 7.4). To this solution, 1 µL of nuclease-free water, 3 µL 
of sodium tetraborate (1 M, pH 8.5) and 5 µL of Quasar 570 (BioSearch Technologies) or 
Cy5 (AAT Bioquest) N- hydroxysuccinimide ester (20 mM) dissolved in anhydrous DMF 
were added. The reaction mixture was then incubated at room temperature for 6 hours. 
Subsequently, the generated fluorescent oligonucleotides were purified by nucleotide 
removal kit (Qiagen) and then further purified via an HPLC equipped with a C18 column 
(Agilent). The collected fraction was dried in a lyophilizer and stored as a stock probe 
solution at 4°C in 120 µL of nuclease free 1× PBS buffer (pH 7.4).  
3.6.4 Synthesis of cleavable and conventional fluorescent antibodies  
Cleavable fluorescent antibodies (Ab-N3-Cy5) and conventional Cy5 labeled antibodies 
were prepared according to the literature42. Briefly, to 20 µL of 1 mg/mL antibodies 
solution in 1× PBS, 1 nmol of N3-Cy5 or conventional Cy5 N-hydroxysuccinimide ester 
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dissolved in 1 µL of anhydrous DMF and 2 µL of 1 M NaHCO3 were added. The reaction 
mixture was incubated for 15 minutes at room temperature in the dark. Subsequently, the 
N3-Cy5 or conventional Cy5 coupled antibodies were purified by size exclusion 
chromatography using Bio-Gel P-6 (Bio-Rad Laboratories). 
3.6.5 Cell culture and fixation  
Hela CCL-2 cells (ATCC) were maintained in Dulbelcco’s modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal bovine serum, 100 g/mL streptomycin and 100 
U/mL penicillin in a humidified atmosphere at 37 °C with 5% CO2. Cells were plated on 
chambered coverglass (0.2 mL medium/chamber) (Thermo scientific) and allowed to reach 
60% confluency in 1-3 days.  
 Cultured HeLa CCL-2 cells were first washed with 1× PBS at room temperature 
for 5 min, and then fixed with fixation solution (4% formaldehyde (Polysciences) in 1× 
PBS) at room temperature for 10 min. Subsequently, cells were washed two times with 1× 
PBS at room temperature, each for 5 min. The fixed cells were permeabilized with 70% 
EtOH at 4°C overnight.  
3.6.6 Labeling of RNA with the direct staining approach  
To 100 µL of RNA pre-decoding hybridization buffer (100 mg/mL dextran sulfate, 1 
mg/mL Escherichia Coli tRNA, 2 mM vanadyl ribonucleoside complex, 20 µg/mL bovine 
serum albumin and 10% formamide in 2× saline-sodium citrate (SSC)) was added 4 µL of 
stock probe solution. Then the mixture was vortexed and centrifuged to obtain the direct 
staining hybridization solution. The direct staining hybridization solutions containing 
cleavable and conventional fluorescent oligonucleotides were used for BoCFO-based RNA 
analysis and conventional RNA FISH, respectively.  
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 Fixed Hela CCL-2 cells were washed with wash buffer (10% formamide in 2× SSC, 
2 mM vanadyl ribonucleoside complex) for 5 min, subsequently incubated with the direct 
staining hybridization solution at 37°C overnight. The stained cells were washed two times 
with wash buffer, each at 37 °C for 30 min, and then equilibrated with GLOX buffer (0.4% 
glucose, 10 mM Tris HCl in 2× SSC) for 1-2 min. Subsequently, the stained cells were 
imaged in freshly prepared GLOX solution (0.37 mg/mL gluocose oxidase, 1% catalase, 
0.4% glucose and 10 mM Tris HCl in 2× SSC).  
3.6.7 Labeling of RNA with the indirect staining approach  
Unlabeled pre-decoding oligonucleotides belonging to one library (each at a scale of 25 
pmol) were dissolved in 100 µL of nuclease-free 1× PBS buffer (pH 7.4) to obtain the RNA 
pre-decoding oligonucleotides stock solution. To 100 µL of RNA pre-decoding 
hybridization buffer was added 1 µL of the RNA pre-decoding oligonucleotides stock 
solution to obtain the RNA pre-decoding hybridization solution. Fixed Hela CCL-2 cells 
were incubated with the RNA pre-decoding hybridization solution at 37°C overnight. Cells 
were washed with wash buffer two times, each at 37°C for 30 min. 
 To 100 µL of decoding hybridization buffer (100 mg/mL dextran sulfate, 2mM 
vanadyl ribonucleoside complex and 10% formamide in 2× SSC), 4 µL of stock probe 
solution was added to obtain the decoding hybridization solution. Subsequently, cells were 
incubated with the decoding hybridization solution at 37°C for 30 min. Then the stained 
cells were washed once with wash buffer at 37°C for 30 min and subsequently imaged in 
GLOX solution.  
3.6.8 Labeling of genomic locus 4p16.1 with the indirect staining approach  
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Unlabeled pre-decoding oligonucleotides belonging to the 4p16.1 library (each at a scale 
of 25 pmol) were dissolved in 500 µL of nuclease-free 1× PBS buffer (pH 7.4) to obtain 
the 4p16.1 pre-decoding oligonucleotides stock solution. To 100 µL of DNA pre-decoding 
hybridization buffer (100 mg/mL dextran sulfate, 50% formamide in 2× SSCT (0.1% 
Tween-20 in 2× SSC)), 8 µL of the 4p16.1 pre-decoding oligonucleotides stock solution 
was added. Then the mixture was vortexed and centrifuged to obtain the 4p16.1 pre-
decoding hybridization solution.  
 Fixed Hela CCL-2 cells were washed once with 1× PBS for 1 min, and then 
incubated with 1× PBST (0.1% Tween-20 in 1× PBS) for 1 min. Subsequently, cells were 
incubated with 0.5% Triton-X 100 in 1× PBS for 10 min, followed by 1× PBST for 2 min. 
After that, cells were treated with 0.4 mg/mL RNase A in 1× PBST at 37 °C for 15 min 
and washed with 1× PBS for 5 min. Cells were then incubated with 0.1 M HCl for 5 min, 
and washed with 2× SSCT three times, each for 2 min. Subsequently, cells were washed 
with 70% formamide in 2× SSCT for 5 min, and incubated in the same solution at 78 °C 
for 20 min and then at 60 °C for 20 min. After cooling to room temperature, cells were 
incubated with 70% formamide in 2× SSCT for 15 min, followed by the incubation with 
the 4p16.1 pre-decoding hybridization solution at 78 °C for 10 min. After that, cells were 
transferred to a humidified chamber and incubated at 37 °C overnight. Then cells were 
washed with 2× SSC at 60 °C for 15 min, 2× SSC at room temperature for 10 min, and 
0.2× SSC at room temperature for 10 min.  
 To 100 µL of decoding hybridization buffer, 4 µL of stock probe solution was added 
to obtain the decoding hybridization solution. The decoding hybridization solutions 
containing cleavable and conventional fluorescent oligonucleotides were used for BoCFO-
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based DNA analysis and conventional DNA FISH, respectively. Cells were then incubated 
with the decoding hybridization solution at 37 °C for 30 min. Subsequently, cells were 
washed with wash buffer at 37 °C for 30 min. After that, cell nuclears were stained with 
the 4’, 6-diamidino-2-phenylindole (DAPI) solution (5ng/mL in wash buffer). Cells were 
then imaged in GLOX solution.  
3.6.9 Labeling of protein Ki67  
Fixed Hela CCL-2 cells were washed with 1× nuclease free PBS for 5 min, and 
subsequently blocked in 1× blocking buffer (1% nuclease-free bovine serum albumin, 
0.1% Triton X-100 in 1× nuclease free PBS) at room temperature for 1 h. The blocked cells 
were incubated with 5 µg/mL cleavable Cy5 or conventional Cy5 labeled rabbit anti-Ki67 
(Fisher Scientific) in 1× blocking buffer at room temperature for 1 h. Then the stained cells 
were washed with 0.1% Triton X-100 in nuclease free 1× PBS for three times, each for 10 
min, and imaged in GLOX solution.  
3.6.10 Fluorophore cleavage  
The stained cells were incubated with 100 mM aqueous TCEP solution (pH 9.5) at 37 °C 
for 30 min. Subsequently, cells were washed with 1× PBS for two times, each for 5 min, 
and then washed with 70 % EtOH for two times, each for 10 min. After that, cells were 
imaged in GLOX solution.  
3.6.11 Effects of the TCEP treatment on nucleic acids integrity  
Fixed Hela CCL-2 cells were incubated with and without 100 mM TCEP (pH 9.5) at 37 °C 
for 24 h. Subsequently, cells were washed with 1× PBS for two times, each for 5 min, and 
then washed with 70% EtOH for two times, each for 10 min. After that, mRNA actin beta 
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(ACTB), marker of proliferation Ki-67 (MKI67) and genomic locus 4p16.1 were labeled 
using the direct or indirect staining approach, and then imaged in GLOX solution. 
 mRNA glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in fixed Hela CCL-
2 cells were stained by ON-N3-Quasar 570 using the indirect staining approach. The stained 
cells were imaged in GLOX solution, and then incubated with 100 mM TCEP (pH 9.5) at 
37 °C for 30 minutes. Subsequently, through cycles of hybridization, imaging and 
cleavage, mRNA GAPDH in the same set of cells was detected sequentially by decoding 
probes ON-N3-Cy5 and ON-N3- Quasar 570.  
3.6.12 Quantification of co-localized spots  
Raw images of the same cell in different hybridization cycles were aligned to the same 
coordination system established by the images collected in the first hybridization cycle 
based on one specific spot reappearing in each cycle. Fluorescent spots in each image were 
then identified and localized by using SpotDetector developed by J. C., Olivo Marin with 
appropriate threshold. Spots in the first hybridization cycle with the distance less than 2 
pixels (320 nm) to those in the second hybridization cycle were extracted as the barcodes, 
which corresponded to a potential mRNA molecule. Spots in the third hybridization cycle 
that shared the distance less than 2 pixels (320 nm) with the barcodes were identified as 
the reappearance of the barcodes. And the barcode reappearance percentage in the third 
hybridization cycle was then calculated.  
3.6.13 Multiplexed single-cell in situ nucleic acids analysis  
Fixed Hela CCL-2 cells were incubated with unlabeled pre-decoding oligonucleotides 
libraries, and then with cleavable Quasar 570 and Cy5 labeled decoding oligonucleotides 
simultaneously to label mRNA MKI67 and GAPDH using the indirect staining approach.  
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 Fixed Hela CCL-2 cells were incubated with cleavable Cy5 labeled 
oligonucleotides to label RNA using the direct or indirect staining approach. The stained 
cells were imaged in GLOX solution, and then incubated with 100 mM TCEP (pH 9.5) at 
37 °C for 30 minutes. Through cycles of hybridization, imaging and cleavage, mRNA 
Topoisomerase I (TOP1), V-akt murine thmoma viral oncogene homolog 1 (AKT1), 
transferrin receptor (TFRC), breast cancer 1 (BRCA1), MKI67, breast cancer 2 (BRCA2), 
GAPDH, polymerase II polypeptide A (POLR2A), ACTB and PR domain containing 4 
(PRDM4) were detected sequentially. For control experiments, fixed HeLa CCL-2 cells 
were incubated with conventional Cy5 labeled oligonucleotides to label RNA using the 
direct staining approach.  
3.6.14 Integrated protein, RNA and DNA analysis  
Fixed Hela CCL-2 cells were incubated cleavable Cy5 labeled rabbit anti-Ki67 to stain 
protein Ki67. The stained cells were imaged in GLOX solution. After fluorophore cleavage 
with TCEP, cells were imaged again in GLOX solution. Subsequently, the same set of cells 
were incubated with cleavable Cy5 labeled oligonucleotides to detect mRNA MKI67 using 
the indirect staining approach. The stained cells were imaged in GLOX solution. After 
fluorophore cleavage with TCEP, cells were imaged again in GLOX solution. After that, 
the same set of cells were incubated cleavable Cy5 labeled oligonucleotides to label 
genomic locus 4p16.1 using the indirect staining approach. The stained cells were imaged 
in GLOX solution. 
3.6.15 Imaging and data analysis  
Stained cells were imaged under a Nikon Ti-E epifluorescence microscope equipped with 
a 100× objective, using a 5 µm Z range and 0.3 µm Z spacing. Images were captured using 
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a CoolSNAP HQ2 camera and analyzed with NIS-Elements Imaging software. Chroma 
filters 49004 and 49009 were used for Quasar 570 and Cy5, respectively. Fluorescent spots 
were identified computationally using an image processing program8. Excel (Microsoft) 
was used to calculate the P-values (student’s t test) and to analyze expression correlation 
between different RNA species and also between RNA and protein. 
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CHAPTER 4 
HIGHLY SENSITIVE AND MULTIPLEXED IN SITU PROTEIN PROFILING WITH 
CLEAVABLE FLUORESCENT TYRAMIDE REVEALS HUMAN NEURONAL 
HETEROGENEITY 
4.1 Abstract 
Comprehensive single-cell protein profiling with a wide range of abundances in intact 
tissue is crucial for our understanding of health and disease. Herein, we report highly 
sensitive and multiplexed in situ protein profiling technique using cleavable fluorescent 
tyramide (CFT). In this method, antibodies tethered to horseradish peroxidase (HRP) are 
utilized to recognize their target proteins and catalyze the enzymatic deposition of CFT. 
After fluorescence imaging and data storage, fluorophores bound to protein targets are 
efficiently cleaved, and simultaneously HRP is deactivated without loss of protein targets 
antigenicity. This approach has the potential to quantify more than 50 different protein 
targets in single-cell in intact tissue at optical resolution through continuous cycles of target 
recognition, fluorescence imaging, and fluorophore cleavage. Using this method, we 
investigated the neuronal heterogeneity in distinct subregions of human hippocampus. This 
single-cell in situ protein profiling approach will bring insights into signaling network 
analysis, molecular diagnosis, and targeted cellular therapies. 
4.2 Introduction 
Comprehensive protein profiling in single-cell in intact tissue can reveal the gene 
expression regulation, spatial organization, and interactions of diverse cell types in 
complex multicellular organisms. Significantly, it holds promise to expand our 
understanding of the function of heterogeneous biological systems, such as developing 
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embryos, brain tissues, and solid tumors1. Immunofluorescence (IF) and 
immunohistochemistry (IHC) techniques have been the gold standard to quantify proteins 
in tissue samples. However, due to spectral overlap of commonly available organic 
fluorophores2-4 limits multiplexing capability. 
 Recently, to increase multiplexing capacity, a number of methods have been 
explored5-13. Nonetheless, the existing techniques have low detection sensitivity as 
detection tags are directly conjugated to antibodies. Therefore, quantification of protein 
with low expression level is hindered with these methods, especially for highly 
autofluorescent tissues, such as formalin-fixed, paraffin-embedded (FFPE) tissues14. 
Moreover, as current methods require pixel-by-pixel sample analysis12, 13 or high 
magnification objectives and long exposure time to detect protein targets, limits its sample 
throughput5-11. 
 Herein, we present a highly sensitive and multiplexed in situ protein profiling 
approach with cleavable fluorescent tyramide (CFT), which has potential to detect and 
quantify >50 different protein targets in intact tissue at single-cell resolution. As illustrated 
in Figure 4.4.1A, this in situ protein profiling technology has four major steps. First, an 
antibody coupled to horseradish peroxidase (HRP) are used to its protein targets. In the 
second step, HRP catalyzes the enzymatic deposition of CFT on the tyrosine residues of 
the endogenous proteins in close proximity. In the third step, fluorescent images are 
captured to acquire protein expression profiles. Finally, the fluorophores attached to the 
tyramide are chemically cleaved, and HRP is deactivated simultaneously, which enables 
the initiation of next analysis cycles. Through reiterative cycles of target binding, imaging 
and fluorophores cleavage, and HRP deactivation, a large number of different proteins with 
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a broad range of expression levels can be detected and quantified in intact tissue at single-
cell resolution. 
4.3 Results and discussion 
To achieve a large number of protein quantification in single-cell, we designed and 
synthesized CFT (tyramide-N3-Cy5) (Figure 4.4.1B) by coupling Cy5 to tyramide through 
an azide-based linker11. The detailed synthesis and characterization of CFT is described in 
the method section (Scheme 4.5.1). 
 To assess the detection sensitivity of our technique, we compared it with direct and 
indirect immunofluorescence. We applied these three methods to stain protein Ki67 in 
HeLa cells with the same concentration of primary antibodies (Figure 4.4.2A-C). This 
method is ~88 and ~35 times more sensitive than direct and indirect immunofluorescence, 
respectively, without loss of staining resolution (Figure 4.4.2D). These results suggest that 
our approach can quantify proteins with low expression level with extremely high 
sensitivity and dramatically reduces the imaging time. 
A critical requirement for the success of this highly sensitive protein profiling 
technique is to erase fluorescence signals without affecting protein antigenicity efficiently. 
We evaluated fluorophore cleavage efficiencies at a different temperature to search for 
optimize condition. To do that, we stained Ki67 protein in HeLa cells with HRP conjugated 
primary antibodies and tyramide-N3-Cy5. After fluorescence imaging, we subsequently 
incubated with tris(2-carboxyethyl) phosphine (TCEP) at 37°C, 50°C and 65°C for 30 
minutes, over 85%, 90% and 95% of the staining signals were removed, respectively 
(Figure 4.4.3). To examine whether protein antigenicity remains at those different 
temperature, we incubated HeLa cells with TCEP at 37°C, 50°C and 65°C for 24 hours, 
	 112	
and subsequently stained Ki67 protein with tyramide-N3-Cy5. We also stained Ki67 
protein as a control without any pretreatment. We observed the cells pretreated with TCEP 
at 37°C and 50°C had retained similar intensities pattern to the control cells; while cells 
incubated at 65°C, have only about half of the control intensities (Figure 4.4.4). Next, we 
tested the cleavage kinetics of stained cells at 50°C by incubating with TCEP for 5, 15, 30 
and 60 minutes. The results suggest the TCEP treatment at 50°C for 30 min (Figure 4.4.5) 
is the ideal condition to achieve the maximum cleavage efficiency while preserving the 
protein antigenicity. 
 To test whether TCEP cleave fluorophore and can deactivate HRP simultaneously, 
we stained proteins ILF3 (Figure 4.4.7A), HMGB1, HDAC2, TDP43, PABPN1, hnRNP 
A1, nucleolin, H4K16ac, hnRNP and Nucleophosmin (Figure 4.4.6) in HeLa cells using 
Corresponding HRP conjugate primary antibodies and tyramide-N3-Cy5. Fluorescence 
signals were efficiently erased after incubation with TCEP at 50°C for 30 minutes, yielding 
the on/off ratios of over 10:1 (Figure 4.4.7C, D, 4.4.6). The results validated that the TCEP 
can deactivate HRP and remove protein staining signals efficiently generated by CFT, 
simultaneously.  
 To assess the feasibility of applying CFT for multiplexed single-cell in situ protein 
analysis, we stained ten distinct protein in HeLa cells. Through reiterative cycles of 
staining, imaging, and signal removal and HRP deactivation, proteins HMGB1, HDAC2, 
TDP43, PABPN1, hnRNP A1, Nucleolin, H4K16ac, hnRNP K, ILF3, and Nucleophosmin 
were unambiguously detected with corresponding HRP conjugate primary antibodies and 
tyramide-N3-Cy5 in the same set of cells (Figure 4.4.8). We also labeled these ten protein 
targets with conventional signal amplification (TSA) assays using Cy5 labeled tyramide 
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(Figure 4.4.9) in 10 different set of cells. The protein distribution patterns obtained by our 
CFT-based approach closely resemble those obtained by conventional TSA assays. We 
also compared mean protein expression levels per cell of the ten protein targets by the two 
methods. The results obtained using two methods closely resemble with each other for all 
ten proteins with various expression levels (Figure 4.4.10A). Comparison of the two 
methods yields an R2 value of 0.99 with a slope of 1.13 (Figure 4.4.10B). These results 
validate that our CFT-based approach enables quantitative and comprehensive protein 
profiling in individual cells in situ. 
 We investigated protein expression heterogeneity in HeLa cells (genetically 
identical), by exploring the distribution of the single cell protein abundances. For all the 
ten measured proteins, the square of the expression standard deviation is much higher than 
the mean expression levels (Figure 4.4.11A). These suggest that those proteins are 
generated in translational bursts, instead of at a constant rate15. We also explored the 
pairwise expression correlation coefficient of the ten measured proteins and calculated the 
correlation coefficient of corresponding each protein pair (Figure 4.4.11B). Employing a 
hierarchical clustering algorithm, we found a group of eight proteins with significantly 
correlated expression patterns (Figure 4.4.11B). Indeed, all the eight proteins in the 
identified group found to be involved in the transcriptional regulation and processing 
related pathways16-23. 
 Formalin-fixed, paraffin-embedded (FFPE) tissues are the most common type of 
preserved clinical samples, used broadly for routine diagnosis and to study disease 
mechanisms24. To demonstrate the feasibility of employing CFT to profile partly degraded 
proteins25 in highly auto-fluorescent FFPE tissues14, we labeled eight proteins sequentially 
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using HRP conjugated primary antibodies and tyramide-N3-Cy5 in the human 
hippocampus. With eight reiterative staining cycles, proteins NeuN, PABPN1, HMGB1, 
TDP43, hnRNP A1, hnRNP K, ILF3, and nucleophosmin were successfully detected and 
quantified (Figure 4.4.12) in the FFPE tissue. We studied the neuronal heterogeneity and 
their spatial organization in the human hippocampus with these protein profiling results. 
We used neuronal marker NeuN26 to identify mature neurons in the examined tissue, and 
calculated the protein expression levels in more than 6000 individual neurons. We then use 
viSNE27 algorithm to cluster neurons based on their protein expression profiles (Figure 
4.4.13, 4.4.14). We identified 10 clusters (Figure 4.4.15A) and mapped those clusters of 
cells back to their spatial location in the tissue (Figure 4.4.15B, 4.4.16, 4.4.17). We 
observed that distinct subregions of the hippocampus comprised of neurons from different 
clusters. For example, dentate gyrus (DG) consists all the clusters except cluster 7, while 
the Cornu Ammonis (CA) fields are mainly dominated by clusters 3,6,7 and 8. Cluster 7 
within the CA field only appears in CA1, CA2, and CA3, but not in CA4 (Figure 4.4.18A). 
In the DG, cluster 2 is the primary cell class in the regions of interest (ROI) 1-5. In contrast, 
other subregions of DG are mainly composed of clusters 1, 3, 4, 9 and 10 (Figure 4.4.18B). 
These results suggest that our CFT-based method allows multiplexed single-cell protein 
profiling in FFPE tissues with intact spatial resolution. Moreover, it enables us to 
investigate different cell type compositions and their spatial organizations in intact tissues. 
 In summary, we have designed and synthesized successfully cleavable fluorescent 
tyramide, and demonstrated it in FFFE tissues to detect and quantify multiple protein 
molecules in single-cell in situ. Significantly, applying this method, we have shown that 
distinct subregions of the human hippocampus composed of different neuron clusters. This 
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approach has enhanced detection sensitivity and high sample throughput, compared to 
other protein profiling technologies. The number of proteins that can be analyzed using our 
CFT-based method depends on the number of protein staining cycles. TCEP can effectively 
erase the fluorescence signals and simultaneously deactivate HRP within 30 minutes. We 
validated that TCEP does not affect the antigenicity of proteins even after incubation for at 
least 24 hours. Therefore, we envision that our CFT-based approach has the potential to 
quantify more than 50 different protein targets in the same tissue. Additionally, cleavable 
fluorescent tyramide can be applied other fields of research, such as RNA or DNA in situ 
hybridization28 and metabolic analysis. This comprehensive molecular profiling platform 
will provide insights into systems biology, cell signaling regulation, cellular 
microenvironment, cell heterogeneity, molecular diagnosis, and targeted cellular therapy.  
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4.4 Figures 
 
Figure 4.4.1 A) Highly sensitive and multiplexed in situ protein profiling with cleavable 
fluorescent tyramide. Protein targets are stained with HRP conjugated antibodies and 
cleavable fluorescent tyramide. After imaging, the fluorophores are chemically cleaved and 
simultaneously the HRP is deactivated. Through cycles of target staining, fluorescence 
imaging, fluorophore cleavage and HRP deactivation, comprehensive protein profiling can 
be achieved in single cells in situ. 
B) Structure of cleavable fluorescent tyramide, tyramide-N3-Cy5. 
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Figure 4.4.2 Protein Ki67 in HeLa cells are stained by (A) direct immunofluorescence (IF), 
(B) indirect IF, and (C) cleavable fluorescent tyramide (CFT). The images in (A), (B) and 
(C) are captured with the exposure time of 1 second, 300 millisecond, and 15 millisecond, 
respectively. (D) Normalized staining intensities of 30 different positions in (A), (B) and 
(C). The y-axis in (D) is on a logarithmic scale. Scale bars, 25 µm. 
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Figure 4.4.3 (A) Protein Ki67 in HeLa cells is stained with tyramide-N3-Cy5. (B) The 
stained cells are incubated with TCEP at 37°C for 30 minutes. (C) Fluorescence intensity 
profile corresponding to the red line and green line positions in (A) and (B). (D) Protein 
Ki67 in HeLa cells is stained with tyramide-N3-Cy5. (E) The stained cells are incubated 
with TCEP at 50°C for 30 minutes. (F) Fluorescence intensity profile corresponding to the 
red line and green line positions in (D) and (E). (G) Protein Ki67 in HeLa cells is stained 
with tyramide-N3-Cy5. (H) The stained cells are incubated with TCEP at 65°C for 30 
minutes. (I) Fluorescence intensity profile corresponding to the red line and green line 
positions in (G) and (H). (J) Fluorophore cleavage efficiency at different reaction 
temperatures (n = 30 positions). Scale bars, 20 µm. 
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Figure 4.4.4 After incubation with TCEP at (A) 37°C, (B) 50°C and (C) 65°C for 24 hours, 
or (D) without any TCEP pre-treatment, protein Ki67 in HeLa cells is stained with 
tyramide-N3-Cy5. (E) The obtained signal intensities with TCEP pre-treatment at different 
temperatures and without any pre-treatment (control) (n = 30 positions). Scale bars, 20 μm.  
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Figure 4.4.5 A) Protein Ki67 in HeLa cells is stained with tyramide-N3-Cy5. (B) The 
stained cells are incubated with TCEP at 50°C for 5 minutes. (C) Fluorescence intensity 
profile corresponding to the red line and green line positions in (A) and (B). (D) Protein 
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Ki67 in HeLa cells is stained with tyramide-N3-Cy5. (E) The stained cells are incubated 
with TCEP at 50°C for 15 minutes. (F) Fluorescence intensity profile corresponding to the 
red line and green line positions in (D) and (E). (G) Protein Ki67 in HeLa cells is stained 
with tyramide-N3-Cy5. (H) The stained cells are incubated with TCEP at 50°C for 30 
minutes. (I) Fluorescence intensity profile corresponding to the red line and green line 
positions in (G) and (H). (J) Protein Ki67 in HeLa cells is stained with tyramide-N3-Cy5. 
(K) The stained cells are incubated with TCEP at 50°C for 60 minutes. (L) Fluorescence 
intensity profile corresponding to the red line and green line positions in (J) and (K). (M) 
Fluorophore cleavage efficiency at different reaction time (n = 30 positions). Scale bars, 
20 µm.  
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Figure 4.4.6 Different proteins in HeLa cells are stained with HRP conjugated antibodies 
and tyramide-N3- Cy5 (the first column). The stained cells are incubated with TCEP (the 
second column). Subsequently, the cells are incubated with tyramide-N3-Cy5, again (the 
third column). Fluorescence intensity profiles corresponding to the red, blue and green line 
positions in the staining, cleavage and restaining images (the fourth column). Scale bars, 
15 µm.  
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Figure 4.4.7 A) Protein ILF3 in HeLa cells is stained with HRP conjugated antibodies and 
tyramide-N3-Cy5. B) Cy5 is cleaved by TCEP. C) Cells are incubated with tyramide-N3-
Cy5, again. D) Fluorescence intensity profile corresponding to the red, blue and green line 
positions in (A), (B) and (C). Scale bars, 20 µm. 
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Figure 4.4.8 Ten different proteins are stained sequentially with the corresponding HRP 
conjugated antibodies and tyramide-N3-Cy5 in the same set of HeLa cells. Scale bars, 40 
µm.  
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Figure 4.4.9 Ten different proteins are stained with the corresponding HRP conjugated 
antibodies and Cy5 labeled tyramide in different HeLa cells. Scale bars, 40 µm. 
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Figure 4.4.10 (A) Mean expression level per cell (n = 200 cells) of 10 different proteins 
measured by immunofluorescence (IF) with cleavable fluorescent tyramide (CFT) and 
conventional immunofluorescence with tyramide signal amplification (TSA). (B) 
Comparison of the results obtained by immunofluorescence with CFT and TSA yields R2 
= 0.99 with a slope of 1.13. The x and y axes in (B) are on a logarithmic scale.  
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Figure 4.4.11 Protein expression heterogeneity and correlation. (A) Histograms of the 
expression level per cell of the 10 measured proteins. (B) Correlation of the expression 
levels of the 10 measured proteins and the hierarchical clustering tree. The upper triangle 
shows the expression correlation coefficient of each protein pair. The lower triangle 
displays the color corresponding to the correlation coefficient. And the protein names are 
shown in the diagonal. A group of proteins identified by a threshold on the cluster tree 
(dashed line) is indicated by the black box in the matrix and the red lines on the tree.  
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Figure 4.4.12 Eight different proteins are detected sequentially with HRP conjugated 
antibodies and tyramide-N3-Cy5 in the FFPE human brain tissue. Scale bars, 200 µm. 
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Figure 4.4.13 Distribution of single-cell protein expression in viSNE plots.  
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Figure 4.4.14 The distinct protein expression patterns in the 10 cell clusters and the 
percentage of cells in each cluster. 
 
Figure 4.4.15 A) Over 6000 neurons in a human hippocampus are partitioned into 10 
clusters. B) Anatomical locations of the individual neurons from the 10 clusters in the 
DG (1-17), CA1 (a-e), CA2 (f), CA3 (g,h) and CA4 (i-k). Scale bars, 2 mm. 
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Figure 4.4.16 Zoom-in views of different regions of interest (ROI) in the dentate gyrus 
(DG) in Figure 4B. Scale bars, 200 µm.  
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Figure 4.4.17 Zoom-in views of different ROI in the Cornu Ammonis (CA) fields in 
Figure 4B. Scale bars, 500 µm.  
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Figure 4.4.18 (A) The DG and CA fields are composed of neurons from different cell 
clusters. (B) Varied ROI in the DG are composed of neurons from different cell clusters.  
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4.5 Schemes 
 
Scheme 4.5.1 Synthesis of tyramide-N3-Cy5. Reagents and conditions: (i) DSC, DMAP, 
DMF, rt, 30 min; and then tyramine hydrochloride, DIPEA, rt, 2 h.  
4.6 Methods 
4.6.1 General information 
Chemicals and solvents were purchased from Sigma-Aldrich or TCI America and were 
used directly without further purification, unless otherwise noted. Bioreagents were 
purchased from Invitrogen, unless otherwise indicated. 1H-NMR and 13C-NMR were taken 
on Varian Innova 500 MHz NMR spectrometers. Chemical shifts are reported in parts 
permillion (ppm) downfield from tetramethylsilane (TMS). Data are reported as follows: 
chemicalshift, multiplicity: singlet (s), doublet (d), triplet (t), multiplet (m), coupling 
constants J in Hz, and integration. HRMS was performed by the Arizona State University 
mass spectrometry facility.  
4.6.2 Synthesis of the tyramide-N3-Cy5  
Tyramide-N3-Cy5 (2): The compound 1 prepared accordingly to the literature10 was 
further purified by semi-preparative reverse phase HPLC [HPLC gradient: A, 100% 0.1 M 
TEAA; B, 100% MeCN; 0-2 min, 5% B (flow 2-5 ml/min); 2-15 min, 5-22% B (flow 5 
ml/min); 15-20 min, 22-30% B (flow 5 ml/min); 20-30 min, 30-35% B (flow 5 ml/min); 
30-32 min, 35-95% B (flow 5 ml/min); 32-35 min, 95% B (flow 5 ml/min); 35- 37 min, 
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95-5% B (flow 5 ml/min); 37-40 min, 5% B (flow 5-2 ml/min)]. The fraction with retention 
time 25.6 min was collected and dried completely under reduced pressure. The purified 
compound 1 (3.9 mg, 4.86 µmol) was co-evaporated with anhydrous DMF (1 ml) and then 
dissolved in anhydrous DMF (300 µL). N, N'-disuccinimidyl carbonate (DSC) (6.2 mg, 
24.3 µmol) in 40 µL of anhydrous DMF and 4-dimethylaminopyridine (DMAP) (3.0 mg, 
24.3 µmol) were added to the above solution and the reaction mixture was stirred for 30 
min at room temperature. Subsequently, to this reaction mixture tyramine hydrochloride 
(4.2 mg, 24.3 µmol) and N,N-diisopropylethylamine (DIPEA) (8.2 µL, 48.6 µmol) were 
added and the reaction mixture was stirred for 2 h at room temperature. After completion 
of the reaction, DMF was evaporated completely under reduced pressure. The crude 
product was purified by a preparative silica gel TLC plate (25 X 25 cm; silica gel 60; 
CH3OH:CH2Cl2 = 1:6; Rf = 0.2). Subsequently, the residue was dissolved in 0.1 M TEAA 
buffer/10% CH3CN followed by filtering off undissolved materials by nylon syringe filter 
(0.2 UM). Then the product was further purified by semi-preparative reverse phase HPLC 
[HPLC gradient: A, 100% 0.1 M TEAA; B 100% MeCN; 0-2 min, 5% B (flow 2-5 ml/min); 
2-10 min, 5-22% B (flow 5 ml/min); 10-15 min, 22-30% B (flow 5 ml/min); 15-20 min, 
30-40% B (flow 5 ml/min); 20-25 min, 40- 50% B (flow 5 ml/min); 25-30 min, 50-60% B 
(flow 5 ml/min); 30-32 min, 60-70% B (flow 5 ml/min); 32-35 min, 70-95% B (flow 5 
ml/min); 35-37 min, 95% B (flow 5 ml/min); 37-39 min, 95-5% B, (flow 5 ml/min); 39-42 
min, 5% B (flow 5-2 ml/min)]. The fraction with retention time 14.1 min was collected and 
dried completely under reduced pressure. The residue was co-evaporated twice with water 
(2 ml) to afford compound 2 (1.1 mg, 24%) as a pure blue solid. 1H NMR (500 MHz, 
CD3OD) δ 8.05- 7.96 (m, 2H), 7.87-7.77 (m, 4H), 7.29 (dd, J = 22.1, 8.4 Hz, 2H), 6.98 (d, 
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J = 7.4 Hz, 2H), 6.70 (d, J = 8.1 Hz, 2H), 6.55-6.47 (m, 1H), 6.22 (dd, J = 24.1, 13.4 Hz, 
2H), 4.60 (t, J = 5.9 Hz, 1H), 4.16-3.97 (m, 6H), 3.89-3.84 (m, 1H), 3.73-3.64 (m, 2H), 
3.21-3.10 (m, 4H), 2.59-2.52 (m, 2H), 2.19-2.12 (m, 2H), 1.83-1.70 (m, 4H), 1.70-1.53 (m, 
12H), 1.35-1.22 (m, 6H); HRMS (ESI-, m/z) calcd for C47H58N7O11S2 [(M)-]: 960.3636, 
found: 960.3074.  
4.6.3 Protein staining with cleavable fluorescent tyramide (CFT) in cells  
Cell culture 
HeLa CCL-2 cells (ATCC) were maintained in Dulbelcco’s modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 g/mL 
streptomycin in a humidified atmosphere at 37 °C with 5% CO2. Cells were plated on 
chambered coverglass (0.2 ml medium/chamber) (Thermo Fisher Scientific) and allowed 
to reach 60% confluency in 1-2 days.  
Cell fixation 
Cultured HeLa CCL-2 cells were fixed with 4% formaldehyde at 37°C for 15 min, 
permeabilized with 0.1% (vol/vol) Triton X-100 at room temperature for 15 min, and 
washed 3 times with 1X phosphate-buffered saline (PBS), each for 5 min.  
Endogenous peroxidase blocking  
Fixed and permeabilized HeLa CCL-2 cells were incubated with 0.15% H2O2 in PBT (1X 
PBS, 0.1% (vol/vol) Triton X-100) for 10 min, and then washed 3 times with 1X PBS, each 
for 5 min.  
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Immunofluorescence with CFT  
Fixed and permeabilized HeLa CCL-2 cells were first blocked with 1X blocking buffer 
(1% (wt/vol) bovine serum albumin, 0.1% (vol/vol) Triton X-100, 10% (vol/vol) normal 
goat serum) at room temperature for 1 h. The cells were incubated with HRP conjugated 
primary antibodies at a concentration of 5 µg/mL in 1X blocking buffer for 45 min, and 
then washed 3 times with PBT, each for 5 min. Subsequently, cells were incubated with 10 
pmol/µL tyramide-N3-Cy5 in amplification buffer (0.1 M Boric acid, pH=8.5) for 7 min. 
Cells were quickly washed twice with PBT, followed by 5 min wash with PBT for 3 times. 
Stained cells were washed with GLOX buffer (0.4% glucose and 10 mM Tris HCl in 2X 
saline-sodium citrate (SSC) buffer (300 mM sodium chloride, 30 mM trisodium citrate, pH 
= 7.0)) for 1 min at room temperature, and then imaged in GLOX solution (0.37 mg mL-1 
glucose oxidase and 1% catalase in GLOX buffer). The used primary antibodies include 
HRP conjugated rabbit anti-HMGB1 (Thermo Fisher Scientific; PA5- 22722), HRP 
conjugated rabbit anti-HDAC2 (Abcam; ab195851), HRP conjugated rabbit anti-TDP43 
(Abcam; ab193850), HRP conjugated rabbit anti-PABPN1 (Abcam; ab207515), HRP 
conjugated rabbit anti-hnRNP A1 (Abcam; ab198535), HRP conjugated mouse anti-
Nucleolin (Abcam; ab198492), HRP conjugated rabbit anti-Histone H4 (acetyl K16) 
(Abcam; ab200859), HRP conjugated mouse anti-hnRNP K (Abcam; ab204456), HRP 
conjugated rabbit anti-ILF3 (Abcam; ab206250) and HRP conjugated mouse anti-
Nucleophosmin (Abcam; ab202579).  
To stain protein Ki67, fixed and blocked HeLa CCL-2 cells were incubated with 5 µg/mL 
rabbit anti-Ki67 (Thermo Fisher Scientific; RB1510P1ABX) in 1X blocking buffer for 45 
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min, and then washed 3 times with PBT, each for 5 min. Afterwards, cells were incubated 
with 5 µg/mL HRP conjugated goat-anti-rabbit (Thermo Fisher Scientific; A16110) in 1% 
(wt/vol) bovine serum albumin in PBT for 30 min, followed by 3 times wash with PBT, 
each for 5 min. Subsequently, cells were incubated with 10 pmol/µL tyramide-N3- Cy5 in 
amplification buffer for 7 min. Cells were quickly washed twice with PBT, followed by 5 
min wash with PBT for 3 times. Cells were then imaged in GLOX solution.  
Fluorophore cleavage and HRP deactivation  
To remove the fluorophores and simultaneously deactivate horseradish peroxidase (HRP), 
cells were incubated with tris(2-carboxyethyl)phosphine (TCEP) (100 mM, pH=9.5) at 
50°C for 30 minutes. To explore the cleavage efficiencies under different temperatures, 
cells were incubated with TCEP (100 mM, pH=9.5) at 37°C, 50°C and 65°C for 30 
minutes. To study the cleavage kinetics, cells were incubated with TCEP (100 mM, 
pH=9.5) at 50°C for 5, 15, 30 and 60 minutes. Following the TCEP incubation, cells were 
washed 3 times with PBT and 3 times with 1X PBS, each for 5 min. Cells were then imaged 
in GLOX solution. To evaluate the HRP deactivation efficiencies following the TCEP 
incubation, cells were incubated with 10 pmol/µL tyramide-N3-Cy5 in amplification buffer 
for 7 min. After 2 times quick wash and 3 times 5 min wash with PBT, cells were imaged 
in GLOX solution.  
4.6.4 Conventional immunofluorescence  
The Cy5 labeled primary and secondary antibodies were prepared accordingly to the 
literature10. For direct immunofluorescence, fixed and blocked HeLa CCL-2 cells were 
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incubated with 5 µg/mL Cy5 labeled rabbit anti-Ki67 primary antibodies (Thermo Fisher 
Scientific; RB1510P1ABX) in the 1X blocking buffer for 45 min at room temperature. 
Cells were washed 3 times with PBT, each for 5 min, and then imaged. For indirect 
immunofluorescence, fixed and blocked HeLa CCL-2 cells were incubated with 5 µg/mL 
rabbit anti-Ki67 (Thermo Fisher Scientific; RB1510P1ABX) for 45 min in 1X blocking 
buffer, then washed 3 times with PBT, each for 5 min. Then cells were incubated with 5 
µg/mL Cy5 labeled goat-anti-rabbit (Thermo Fisher Scientific; A16112) in 1% (wt/vol) 
bovine serum albumin in PBT for 30 min, followed by 3 times wash with PBT, each for 5 
min. Cells were then imaged in GLOX solution. 
4.6.5 Multiplexed protein analysis with CFT in cells  
Fixed and blocked HeLa CCL-2 cells were incubated with 5 µg/mL HRP conjugated 
primary antibodies at room temperature for 45 min, and then stained by tyramide-N3- Cy5. 
After imaging, stained cells were incubated with 100 mM TCEP (pH=9.5) at 50°C for 30 
min, followed by the next immunofluorescence cycle. The sequentially used primary 
antibodies include HRP conjugated rabbit anti-HMGB1 (Thermo Fisher Scientific; PA5-
22722), HRP conjugated rabbit anti-HDAC2 (Abcam; ab195851), HRP conjugated rabbit 
anti-TDP43 (Abcam; ab193850), HRP conjugated rabbit anti-PABPN1 (Abcam; 
ab207515), HRP conjugated rabbit anti-hnRNP A1 (Abcam; ab198535), HRP conjugated 
mouse anti-Nucleolin (Abcam; ab198492), HRP conjugated rabbit anti- Histone H4 (acetyl 
K16) (Abcam; ab200859), HRP conjugated mouse anti-hnRNP K (Abcam; ab204456), 
HRP conjugated rabbit anti-ILF3 (Abcam; ab206250) and HRP conjugated mouse anti-
Nucleophosmin (Abcam; ab202579). For control experiments, fixed and blocked HeLa 
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CCL-2 cells were incubated with 5 µg/mL HRP conjugated primary antibodies at room 
temperature for 45 min, and then stained by Cy5 labeled tyramide (PerkinElmer). 
4.6.6 Multiplexed protein analysis with CFT in brain tissues 
Deparaffinization and antigen retrieval  
The brain formalin-fixed paraffin-embedded (FFPE) tissue slide was deparaffinized 3 
times in xylene, each for 10 min. Then, the slide was immersed in 100% ethanol for 2 min, 
95% ethanol for 1 min, 70% ethanol for 1 min, 50% ethanol for 1 min, 30% ethanol for 1 
min, and rinsed with deionized water. Subsequently, the slide was immersed in antigen 
retrieval buffer (10 mM sodium citrate, 0.05% Tween 20, pH=6.0), and water- bathed in a 
pressure cooker for 20 min with the “high pressure” setting. Afterwards, the slide was 
rinsed 3 times with 1X PBS, each for 5 min.  
Multiplexed protein staining in FFPE tissues  
After deparaffinization and antigen retrieval, the brain FFPE tissue was first blocked by 
0.15% H2O2 for 10 min and then washed 3 times with 1X PBS, each for 5 min. The tissue 
was then blocked in 1X blocking buffer at room temperature for 1 h. Subsequently, the 
tissue was incubated with 5 µg/mL biotin conjugated Rabbit anti-NeuN (Abcam; 
ab204681) in 1X blocking buffer for 45 min, and then washed 3 times with PBT, each for 
5 min. Afterwards, the tissue was incubated with 5 µg/mL HRP conjugated streptavidin 
(Abcam; ab7403) in 1% (wt/vol) bovine serum albumin in PBT for 30 min, followed by 3 
times wash with PBT, each for 5 min. Subsequently, the tissue was incubated with 10 
pmol/µL tyramide-N3-Cy5 in amplification buffer for 7 min. The tissue was quickly 
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washed twice with PBT, followed by 5 min wash with PBT for 3 times. After imaging, the 
tissue was incubated with 100 mM TCEP (pH=9.5) at 50°C for 30 min. The tissue was 
imaged again before initiating the next cycle. In the following cycles, the tissue was 
incubated with 5 µg/mL HRP conjugated primary antibodies in 1X blocking buffer for 45 
min. Subsequently, the tissue was stained with tyramide-N3-Cy5 and imaged. After 
incubated with 100 mM TCEP (pH=9.5) at 50°C for 30 min, the tissue was imaged again, 
followed by the next analysis cycle. The sequentially used primary antibodies include HRP 
conjugated rabbit anti-PABPN1 (Abcam; ab207515), HRP conjugated rabbit anti- HMGB1 
(Thermo Fisher Scientific; PA5-22722), HRP conjugated rabbit anti-TDP43 (Abcam; 
ab193850), HRP conjugated rabbit anti-hnRNP A1 (Abcam; ab198535), HRP conjugated 
mouse anti-hnRNP K (Abcam; ab204456), HRP conjugated rabbit anti-ILF3 (Abcam; 
ab206250) and HRP conjugated mouse anti-Nucleophosmin (Abcam; ab202579).  
4.6.7 Imaging and data analysis  
Both stained cells and the FFPE brain tissue were imaged under a Nikon Ti-E 
epifluorescence microscope equipped with 20X objective. Images were taken using a 
CoolSNAP HQ2 camera and Chroma filter 49009. Cell segmentation and intensity 
quantification were processed by NIS-Elements Imaging software. Pseudo-color images 
were generated using ImageJ. Protein expression heterogeneity and correlation were 
analyzed with Excel (Microsoft). The hierarchical clustering was performed with Cluster 
3.0 (http://bonsai.hgc.jp/~mdehoon/software/cluster/). ViSNE maps were generated from 
CYT (https://www.c2b2.columbia.edu/danapeerlab/html/cyt.html)27. 
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SUMMARY 
In summary, we have designed and synthesized novel fluorescent probes and applied them 
to detect and quantify multiple DNA, RNA, and protein molecules in single-cell in situ. 
Using these probes, we have calculated protein expression levels in 6000 individual 
neurons in formalin-fixed, paraffin-embedded (FFPE) brain tissue. Based on protein 
expression heterogeneity, we explored the neuronal heterogeneity and their spatial 
organization in the human hippocampus. Linking molecular cell types with its spatial 
locations to physiological, morphological, and behavioral changes will help us to 
understand brain function, development, and disease. 
 With the ongoing development, single-cell spatial proteomics and transcriptomics 
technologies will advance our understanding of heterogeneous biological systems. For 
example, solid tumors can be studied at a single-cell level to investigate the molecular 
mechanisms of cancer initiation, progression, and metastasis, discover new biomarkers, 
and identify novel drug targets. Additionally, single-cell technologies can be used to 
explore the embryo at various development stages to examine the developmental programs 
and organ formation at the molecular level. 
 Single-cell spatial proteomics and transcriptomics technologies will also have 
broad applications in clinical diagnosis and precision medicine. By interrogating 
interactions among cells in a tissue and mapping regulatory networks within individual 
cells, will significantly accelerate our understanding of the molecular mechanisms of 
diseases, and may discover novel drug targets for more effective cellular targeted therapy. 
By pinpointing alterations in the abundances and positions of various biomolecules in 
single cells, new biomarkers can be discovered. With a comprehensive profiling of a panel 
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of biomarkers, diseases can be precisely diagnosed, and the ideal treatment can be selected. 
Additionally, to adjust the treatment promptly, immune response or efficacy of drugs can 
be monitored during the therapy. Single-cell proteomics and transcriptomics analysis will 
become a cornerstone in precision medicine and biomedical research. 
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